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        MAP kinase phosphatases (MKPs) critically control the activation of MAP 
kinase in immune responses. MKP-2 has been shown to regulate ERK or 
JNK/p38 upon LPS stimulation and plays a role in response to parasite infection. 
However, the functions of MKP-2 in innate immune response to virus infection 
and in macrophage M1/M2 activation are not clear. Here we found that MKP-2 
knockout (KO) mice are resistant to PR8 (H1N1) influenza infection associated 
with increased type-I interferons (IFNs) expression compared with wild type 
(WT) mice. Increased type-I IFNs production in MKP-2 KO macrophages upon 
PR8 infection was associated with enhanced ERK and IRF3 activation. Inhibition 
of ERK abrogated the difference in type-I IFNs expression between WT and KO 
macrophages upon PR8 infection. On the other hand, using gene overexpression 
approach, we found that MKP-2 inhibits macrophage M1 activation and 
inflammation in macrophage-adipocyte interaction through JNK and p38. 
Together, these data demonstrated differential regulation of MAP kinase 
activation by MKP-2 in macrophages on a context-dependent manner and the 
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Chapter 1 Introduction 
1.1 Mitogen-activated protein kinases (MAPKs)  
        MAPKs are evolutionarily conserved regulators that mediate signal 
transduction and play essential roles in various physiological processes (Fig. 1.1) 
(Zhang and Dong 2007). There are three major MAPKs, namely the extracellular 
signal regulated kinases (ERKs), the c-Jun N terminal kinases (JNKs) and the p38 
MAPKs (Qi and Elion 2005). All the MAPKs consist of a Thr-X-Tyr (TXY) 
motif within their activation loop. The phosphorylation of both threonine and 
tyrosine within the activation loop is essential and sufficient for their activation. 
The core MAPK signaling module consists of a three-tier kinase cascade in which 
a MAPK kinase kinase (MKKK or MEKK) phosphorylates and activates a 
MAPK kinase (MKK or MEK). MAPK kinases are dual-specificity protein 
kinases that phosphorylate both the threonine and tyrosine residues of the 
conserved T-X-Y motif and activate the MAPKs (Owens and Keyse 2007). Once 
activated, the MAPKs phosphorylate a wide array of substrates in the cytosol and 
nucleus to regulate diverse genes expression that execute the appropriate 
biological responses including growth, differentiation, development and 
inflammation (Roux and Blenis 2004).  
        The functions of MAPKs are tightly regulated by activators, scaffolds and 
negative regulators, together with which they can form delicate signaling cascades 
in response to different extracellular or intracellular stimulation. MKPs or dual 
specificity phosphatases (DUSPs) have been defined as major negative regulators 
of MAPKs (Zhang and Dong 2007). 
 2 
 
Figure 1. 1 Mammalian MAPK cascades adapted from (Roberts and Der 2007) 
There are three major mammalian MAPK protein kinases, which are commonly activated by 
growth factors and environmental stress. Activated MAPKs phosphorylate various substrates 
including nuclear transcription factors to regulate genes expression in different biological 
responses.  
 
1.2 MAP Kinase phosphatases (MKPs) 
MKPs are known as major negative regulators of MAPKs and are identified 
by their common structural features: a C-terminal catalytic domain containing a 
highly conserved signature motif HCXXXXXR and two Cdc25-like domains. 
They inactivate MAPKs by dephosphorylating both the threonine and tyrosine 
residues within the signature sequences -Thr-X-Tyr- located in the activation loop 
of MAPKs (Liu, Shepherd et al. 2007).  
        There are at least 10 MKPs identified so far and each of them has distinct 
substrate specificity, subcellular localization and regulatory mechanisms (Fig. 
1.2). The MKPs are classfied to three subfamilies according to their localization 
and domain structure. The first group of MKPs is mitogen or stress induced 
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nuclear MKPs including MKP-1, MKP-2, DUSP2 and DUSP5. The second group 
of MKPs is ERK selective cytoplasmic MKPs including MKP-3, MKP-X and 
MKP-4. The final group of MKPs is JNK/p38-selective MKPs including MKP-5, 
MKP-7, and DUSP8 (Caunt and Keyse 2013). All of the MAPKs consist of a 
conserved N-terminal kinase interaction motif, which mediate the interaction 
between MKPs and target MAPKs and a C-terminal catalytic site, which 
dephosphorylates specific MAPKs (Zhang and Dong 2007). 
 
Figure 1. 2 Classification, localization and domain structure of the MKPs adapted from 
(Caunt and Keyse 2013) 
There are three subfamilies of MKPs based on their localization, domain structure and substrate 
specificity. Group 1 MKPs are nuclear located MKPs. Group 2 MKPs are ERK-specific 
cytoplamic MKPs. Group 3 MKPs are JNK/p38-specific MKPs.  
 
1.3 MAPK pathway and inflammation 
        MAPKs are pivotal for processes that are central to inflammatory responses 
such as inflammatory cytokine expression by immune cells (Jeffrey, Camps et al. 
2007). The activation of p38 and JNK is well known to lead to the production of 
various inflammatory cytokines including TNF-α, IL-1, IL-6 and IL-12, which are 
essential for the eradication of infectious microorganisms (Zhang and Dong 2005). 
ERK pathway is activated by upstream tumor progression locus-2 (TPL-2), a 
MEK kinase, in innate immune response to regulate Tnf-α and Il-1β expression 
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(Papoutsopoulou, Symons et al. 2006). 
As major negative regulators of MAPKs, various MKPs have been reported 
important in inflammation and immunity. MKP5 is the first MKP that has been 
shown to play important roles in both innate and adaptive immune responses. 
With the use of the MKP5 KO mice model, Zhang et al. (2004) showed that in 
MKP5 KO mice, JNK activity was selectively increased in primary macrophages 
upon treatment to LPS. Correspondingly, there was increased IL-6 and TNF-α 
production (Zhang, Blattman et al. 2004). The study shed light on the new 
functions of MKPs in immune responses. Subsequently Liu Yusen et al. (2006) 
studied the functions of MKP-1 and found that MKP-1 KO mice had prolonged 
activity of both JNK and p38 with no change in ERK activity, resulting in 
increased innate immune cell responses (Zhao, Wang et al. 2006). In contrast, 
Jeffrey KL et al. (2006) identified PAC-1 (DUSP2) as a positive regulator of 
inflammatory cell signaling. They showed that PAC-1 KO cells had increased 
JNK activity but reduced ERK and p38 activity in response to LPS stimulation 
(Jeffrey, Brummer et al. 2006). In consequence, there were substantial defects in 
the expression of many MAPK-dependent pro-inflammatory genes. This study 
suggested that ERK and p38 are more important in PAC-1 KO mice than JNK in 
the control of inflammatory cytokine gene expression. Since then, a large number 
of studies have been done to investigate the role of MKPs in immune responses 
(Zhang, Reynolds et al. 2009, Al-Mutairi, Cadalbert et al. 2010, Musikacharoen, 
Bandow et al. 2011). 
1.4 MKP-2 
        MKP-2 is a 42-kDa inducible phosphatase known to be up regulated in 
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response to growth factors, oncogenes, phorbol 12-myristate 13-acetate (PMA), 
oxidative stress, and UV light as well as LPS (Cornell, Rodenhouse et al.). Once 
expressed, it is located in the nucleus (Sloss, Cadalbert et al. 2005). High 
expression of MKP-2 is found in various types of immune cells and is therefore 
thought to have an important role in immune responses (Huang, Lin et al. 2012). 
Al-Mutairi, Cadalbert et al. demonstrated that MKP-2 KO bone marrow derived-
macrophages (BMDMs) have enhanced JNK and p38 activation but comparable 
ERK activation compared with WT cells upon LPS stimulation (Al-Mutairi, 
Cadalbert et al.). A corresponding increased inflammatory cytokines production 
was observed in KO BMDMs. The MKP-2 KO mice were further shown to be 
more susceptible to parasite Leishimania Mexicana infection with increased 
Arginase-1 expression and decreased iNOS expression (Al-Mutairi, Cadalbert et 
al.).  
        In this project, we employed infuenza infection model and chronic 
inflammation model during macrophage-adipocyte interaction to study the 
regulatory role of MKP-2 in inflammation and influenza infection.  
1.5 Influenza infection model 
1.5.1 Influenza viruses 
        Influenza viruses are negative-sense, single-stranded and segmented RNA 
viruses belonging to the family of Orthomyxoviridae (Smith and Gray 2010). 
There are 3 types of influenza viruses, namely influenza virus A, B, and C, 
classified on the basis of the antigenic properties of their matrix [M] and 
nucleoprotein [NP] proteins. Of these, Influenza B viruses are less threatening but 
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can still cause epidemics while Influenza C has not been reported to be associated 
with either pandemics or epidemics (Taubenberger and Morens 2008). Being the 
most infectious out of the three, influenza A viruses tend to garner most of the 
attention as they can infect a wide range of hosts including birds, swines, humans 
and other mammals (Webster, Bean et al. 1992) and cause both epidemics and 
pandemics. The genome of influenza A viruses consists of 8 single-stranded RNA 
segments (Fig. 1.3) that encode for 10 proteins. Influenza A viruses can be 
divided into subtypes on the basis of genetic and antigenic differences in their 
main surface glycoproteins, haemagglutinin (HA) and neuraminidase (NA). So far, 
16 HA (H1–H16) and 9 NA (N1–N9) subtypes have been identified in influenza A 
viruses (Subbarao and Joseph 2007). 
 
Figure 1. 3 Schematic representation of the influenza A virus adapted from (Subbarao and 
Joseph 2007) 
Influenza A virus consists of eight RNA genomic segments, each of which is associated with the 
trimeric viral RNA polymerase (PB1, PB2, PA) and coated with multiple nucleoproteins (NPs) to 
form the vRNPs. The outer layer of the lipid envelope is spiked with multiple copies of HA, NA 
and a small number of M2, whereas the M1 molecules keep vRNPs attached to the inner layer.  
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1.5.2 Structure and genetics of the influenza A virus 
        The influenza A virus particle has a lipid envelope that is derived from the 
host cell membrane. Three envelope proteins —HA (rod shaped), NA (mushroom 
shaped) and an ion channel protein M2— are embedded in the lipid bilayer of the 
viral envelope (Fig. 1.3). Inside the M1 inner layer are eight single-stranded 
negative sensed RNA segments that are encapsidated with NP and associated with 
three RNA polymerase proteins —PB1, PB2 and PA — to form the viral 
ribonucleoprotein (vRNP) complex. The virus also encodes a non-structural 
protein (NS) that is expressed in infected cells and a nuclear export protein (NEP) 
(Subbarao and Joseph 2007). 
1.5.3 Influenza epidemic and pandemic 
Influenza viruses are evolutionarily dynamic viruses. Due to the high 
mutation rates of the viruses, an influenza vaccine confers protection for no more 
than a few years. Additionally, the generation of viral escape mutants also renders 
drugs against influenza viruses potentially ineffective (Karlas, Machuy et al. 
2010). The success of the influenza viruses as human pathogen is mainly 
attributed to the fact that they can undergo antigenic shift and antigenic drift. 
Antigenic shift results from the replacement of the existing HA and sometimes 
NA with novel subtypes against which immunity is lacking in humans. Antigenic 
drift involves the accumulation of mutations within the antibody-binding sites in 
the HA, NA or both that abrogates the binding of antibodies (Treanor 2004). 
Consequently, epidemic and pandemic outbreaks could occur. Therefore, 
influenza viruses pose constant threat to public health globally. Seasonal influenza 
 8 
epidemics are estimated to cause 3 to 5 million cases of severe illnesses and about 
250 to 500 thousands of death annually worldwide (WHO, 2009). In the last 500 
years, approximately 14 influenza pandemics happened by the emergence of new 
strains of influenza virus that targeted humans (McGill, Heusel et al. 2009, 
Taubenberger and Kash 2010).  
There are six recorded human pandemics since 1885. Among all the 
pandemics, the most severe pandemic was the 1918 Spanish H1N1 influenza 
pandemic, which was responsible for the death of approximately 40 million 
people or more worldwide (Reid, Taubenberger et al. 2001). Two pandemics 
occurred in 1957 and 1968 in Asia, although not so serious as the one in 1918. A 
recent pandemic occurred in 2009 caused by a H1N1 virus, which is known as 
“swine flu” killed many lives (Chowell, Bertozzi et al. 2009, Garten, Davis et al. 
2009). In 2013, a new avian H7N9 influenza virus, which can infect humans, 
resulted in a mortality rate of roughly 32.4% (Huang, Zhang et al. 2014). The 
emergences of such novel viruses demonstrates that influenza A viruses are still a 
major threat to public health. 
1.5.4 Influenza infection, transmission and replication 
Influenza viruses are mainly transmitted from person to person through the 
air, or contact with contaminated objects/fomites (Mubareka, Lowen et al. 2009). 
Coughing and sneezing, common symptoms of influenza can produce up to 
thousands of droplets containing virus particles. Inhalation of these virus 
containing aerosols is sufficient to cause infection in a healthy individual (Fabian, 
McDevitt et al. 2008). Transmission of virus through contacts, or fomites occurs 
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when nasal secretions from infected individuals appear on their hands and other 
objects. When healthy individuals happen to contact with these objects and touch 
their eyes or noses subsequently, they absorb the virus particles and get infected 
(Carrat, Vergu et al. 2008). 
 
 
Figure 1. 4 Influenza A life cycle adapted from (Das, Aramini et al. 2010) 
Influenza A viruses enter the host cells through the recognition of surface glycoprotein HA by 
sialic acid receptors and transported into the cell in an endocytic vesicle. The vRNPs are 
transported into the nucleus by recognition of the nuclear localization sequences (NLSs) on 
nucleoproteins. In the nucleus, the viral initiates the trancription, replication and tranlation of viral 
mRNA and genome using the host cells machinery. The released vRNPs reach the cell membrane 
to be packaged into new viruses. 
 
 
The process of infection and viral replication were shown in Fig. 1.4. 
Individual influenza virions bind to the host cell surface through the interaction of 
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influenza glycoprotein HA with sialic acid receptors on the surface of epithelial 
cells in the airway (Isin, Doruker et al. 2002). Upon binding, the virus is 
endocytosed and transported to the cell in the endocytic vesicle. The endocytic 
compartment containing the virus is acidified to generate a low pH environment 
in the endsome. The low pH activates the M2 ion channel, which acidifies the 
viral interior and facilitates the release of the vRNP segments into the cytoplasm 
(Schnell and Chou 2008). After being unpacked and released into the cytoplasm, 
the genome segments are transported into the nucleus by recognition of the 
nuclear localization sequences (NLSs) on nucleoproteins (Wu and Pante 2009) 
only when the M1 proteins are dissociated. In the nucleus, replication of positive-
sense mRNA occurs (Shapiro and Krug 1988). The influenza mRNA are 
synthesized using a unique “cap snatching” mechanism that utilizes the 5’cap of 
host pre-mRNAs and subsequently cleaves the host nucleotides from the 
synthesized influenza segment (Dias, Bouvier et al. 2009). The viral mRNA is 
exported to the cytoplasm where they use cell machinery to generate influenza 
proteins. Concomitantly, the negative-sense vRNP segments are produced in the 
nucleus and exported to the cytoplasm for eventual packaging into progeny 
virions which will bud from the cell surface (Leser and Lamb 2005). Detachment 
from the cell takes place when influenza NA cleaves the sialic acid residues 
connecting the virion to the cell surface (Air and Laver 1989). The newly released 
virions travel through the airway until they encounter new cells expressing sialic 
acid receptors and the process starts over again. 
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1.5.5 Host innate immune response to influenza 
The innate immune system is the first line of defense against influenza 
viruses (Wu, Metcalf et al. 2011). Within hours after initial infection, the infected 
host initiates a series of events to limit viral replication and to eliminate the 
viruses. Innate immune cells, including neutrophils, alveolar macrophages, natural 
killer (NK) cells and dendritic cells (DC) play essential roles in the control of 
influenza virus replication (McGill, Heusel et al. 2009). As shown in Fig. 1.5, 
upon entry, influenza viruses replicate in tracheal and bronchial epithelial cells 
which can produce pro-inflammatory cytokines including type-I Interferons 
(IFNs), Interleukin-6 (IL-6) and Tumor Necrosis Factor α (TNF-α) and 
chemokines such as RANTes, Interleukin-8 (IL-8) and Monocyte Chemoattractant 
Protein 1 (MCP-1) (Herold, von Wulffen et al. 2006). Influenza viruses can infect 
resident alveolar macrophages as well which leads to the production of pro-
inflammatory cytokines and chemokines (Kim, Lee et al. 2008). These factors 
lead to the recruitment of more innate immune cells to the lungs post infection 
(P.I.). The infiltrated monocytes will differentiate into macrophages and DCs in 
the lungs (Zaslona, Wilhelm et al. 2009). These innate immune cells have 
multiple mechanisms to detect the components of the viruses to initiate responses 
that are critical for controlling and resolving the infection. 
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Figure 1. 5 Innate immune response to influenza infection in the lung tissues 
Influenza viruses enter and replicate in the lung epithelial cells to trigger chemokines to recruit monocytes 
and neutrophils to lung tissues to induced inflammation. Infiltrated monocytes further differentiate to 
macrophages and dendritic cells. Released viruses from the epithelial cells can be recogonized by alveolar 
macrophages and dendritic cells to induce the production of pro-inflammatory cytokines and chemokines to 
help the host to fight against influenza viruses infection. 
  
        However, antiviral inflammatory responses play as a double-edged sword 
against influenza infection. Excessive inflammation could be detrimental to the 
lung tissues during influenza-induced lung injury by destroying the homeostasis 
of lung tissues (Tisoncik, Korth et al. 2012). Neutrophils are recruited to the site 
of lung tissues after influenza infection and have potent antiviral armour that 
includes oxidants, proteinases and cationic peptides. However, increased duration 
and extent release of these microbicidal compounds into the BALs paradoxically 
can damage lung tissues (Grommes and Soehnlein 2011). Excessive chemokines 
production such as IL-8, MCP-1 and RANTes will also contribute to lung damage 
by recruiting neutrophils to the site of inflammation. Additionally, unregulated 
inflammatory cytokines (such as IL-1, tumour TNF- α and IL-17) that are 
induced can also lead to pathology (Iwasaki and Pillai 2014).  
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1.5.6 Innate recognition of influenza virus and downstream signaling pathways 
Our innate immune system is armed with pathogen recognition receptors 
(PRRs) that can detect microbial infection through the recognition of pathogen-
associated molecular patterns (PAMPs). These PAMPs are molecular motifs that 
are conserved within microbes but absent in host (Kopp and Medzhitov 2003). 
Upon influenza infection, influenza-specific PAMPs are generated (Medzhitov 
2001). Influenza viruses could be recognized by various PRRs (with respective 
ligands indicated): the Toll-like receptor 3 (TLR3) (double-stranded RNA 
(dsRNA)), TLR7 (single-stranded RNA (ssRNA)) and TLR8 (ssRNA) (human 
only); retinoic acid-inducible gene I (RIG-I) (5′-ppp dsRNA) and the NOD-like 
receptor family member NOD-, LRR- and pyrin domain-containing 3 (NLRP3) 
(various stimuli) (Pang and Iwasaki 2012). RIG-I and NLRP3 detect virus PAMPs 
in the cytosol of infected cells, whereas TLR3 and TLR7 (and TLR8 in humans) 
detect viral RNA that has been taken up into the endosomes of sentinel cell. 
1.5.7 Type-I Interferons (IFNs) 
Type-I IFNs, including IFN-α and IFN-β, have long been appreciated for the 
critical roles they play in anti-viral immune responses (Gonzalez-Navajas, Lee et 
al. 2012). The plasmacytoid DCs (pDCs) have been identified as the most potent 
producers of Type I IFNs in response to viral antigens, therefore they are known 
as natural type-I IFNs producing cells (Liu 2005). Besides, alveolar macrophages 
as well as lung epithelial cells are also able to produce type-I IFNs upon influenza 
virus infection (Kallfass, Lienenklaus et al. 2013).  
Type I IFNs can be recognized by a unique heterodimeric IFN-α/β receptor 
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(IFNAR) in an autocrine or paracrine way to induce the transcription of various 
Isgs such as the dsRNA-dependent protein kinase R (PKR) via the Janus 
kinase/signal transducers and activators of transcription (Jak/STAT) pathway (Fig. 
1.6) (Schoggins, Wilson et al. 2011). ISGs can target almost every step in a virus 
life cycle to restrict viral spread, for example cleaving viral mRNA to inhibit viral 
protein synthesis (Schoggins and Rice 2011).  
 
Figure 1. 6 The canonical type I IFNs signalling pathway adapted from (Ivashkiv and Donlin 
2014) 
Type-I IFNs can be recognized by interferon-α receptor (IFNAR, which is composed of the 
IFNAR1 and IFNAR2 subunits) to activate JAK1 and tyrosine kinase 2 (TYK2). Once activated, 
these kinases result in the recruitment of STAT1 and STAT, phosphorylation, dimerization and 
nuclear translocation. The STAT1, STAT2 heterdimers bind to IFN-stimulated response element 
(ISRE) sequences to regulate Isgs expression. 
 
Moreover, type I IFN signalling was recently ascribed a role in functional 
differentiation of myeloid cell subsets during influenza virus infection, including 
monocytes, neutrophils and DCs (Hogner, Wolff et al. 2013). Apart from that, 
type-I IFNs play a key role in the clonal expansion, memory formation and 
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 T cells responses in 
the initial phase of antigen recognition (Kolumam, Thomas et al. 2005, Huber and 
Farrar 2011). 
 
1.5.8 ISGs against influenza virus 
Genetic studies in mice have revealed non-dispensable roles of several ISGs 
— including Myxoma Resistance Proteins (MXs), IFN-inducible transmembrane 
(IFITM) proteins, 2′, 5′-oligoadenylate synthetase (OAS)/RNase L, PKR and 
ISG15 — in limiting influenza virus infection, including replication and spread. 
MX proteins were the first ISGs identified that restrict influenza virus 
infection (Staeheli, Haller et al. 1986). In mice, the Mx1 protein is expressed in 
the nucleus, and blocks influenza viral transcription and replication (Zurcher, 
Pavlovic et al. 1992). It was found that Mx1 inhibits influenza viral replication by 
interacting with the influenza RNP complex and interfering with its assembly by 
disturbing the PB2-NP interaction (Verhelst, Parthoens et al. 2012). 
IFITM proteins restrict the replication of influenza A as well as other viruses 
by blocking virus–host cell membrane fusion following viral attachment and 
endocytosis (Brass, Huang et al. 2009). One member of the IFITM proteins, 
IFITM3 is constitutively expressed in respiratory epithelial cells, macrophages 
and endothelial cells. Deficiency of IFITM3 in mice leads to higher susceptibility 
to influenza infection, highlighting the importance of IFITM3 in innate resistance 
to influenza virus infection (Bailey, Huang et al. 2012). 
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The 2′, 5′- OAS/RNase L system is an innate immunity pathway that 
responds to a PAMP to induce degradation of viral and cellular RNAs thereby to 
block viral infections (Silverman 2007). Upon binding of dsRNA, OAS becomes 
enzymatically active, converting adenosine triphosphate (ATP) into 2′-5′-
oligoadenylate, which functions as a second messenger to activate latent RNase L. 
Activated RNase L degrades viral and cellular ssRNAs to inhibit protein synthesis 
and viral growth (Iwasaki and Pillai 2014). RNase L KO mice are more 
susceptible to influenza virus infection (Silverman 2007). 
The Ser/Thr protein kinase, PKR, is constitutively expressed in mammalian 
cells and can be further increased by type-I IFNs treatment (Hovanessian 1989, 
Meurs, Chong et al. 1990). Activated PKR blocks cellular and viral protein 
synthesis by phosphorylating the α-subunit of the eukaryotic initiation factor 
(eIF2α), thereby inhibiting viral replication in infected cells (Samuel 1993, Gale 
and Katze 1998). Thus, PKR plays a central role in host defense against viral 
infection. Mice that are genetically deficient in PKR are highly susceptible to 
various viral infections, including influenza virus (Balachandran, Roberts et al. 
2000).  
ISG15 is an ubiquitin-like molecule that is highly induced by type-I IFNs 
and plays important roles in innate immunity against several viruses. ISG15 
and/or its conjugation have been reported to inhibit the replication of influenza B 
virus (Yuan and Krug 2001). Furthermore, the ISG15 KO mice are more 
susceptible to both influenza A and B virus infection than wildtype (WT) mice 
(Lenschow, Lai et al. 2007). A recent study demonstrated that IFN-induced ISG15 
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conjugation system can exert its antiviral activity by conjugating ISG15 to a 
specific viral protein such as NS1 in infected cell, thereby inhibiting its function 
and hence virus replication (Zhao, Hsiang et al. 2010). 
        In addition to these well-known ISGs described above, studies have found 
many other ISGs that are capable of blocking influenza virus infection. For 
instance, viperin (also known as RSAD2) blocks influenza virus release by 
interfering with the formation of the lipid raft from which the virus buds (Wang, 
Hinson et al. 2007). Cholesterol 25-hydroxylase (Ch25h), which is expressed in 
response to tyep-I IFNs signalling, converts cholesterol to soluble 25-
hydroxycholesterol (25HC) that can affect the replication of enveloped influenza 
virus through blocking viral fusion (Blanc, Hsieh et al. 2013, Liu, Aliyari et al. 
2013). Tripartite motif-containing protein 22 (TRIM22) blocks viral genome 
encapsidation to suppress influenza virus infection (Clarke, Aragam et al. 2013).  
Thus, ISGs play non-redundant roles in restricting influenza virus 
replication in vivo. 
1.5.9 Inflammatory cytokines and chemokines 
PAMPs generated from the influenza virus lead to the production of pro-
inflammatory cytokines, such as IL-6, IL-1β and TNF-α. These pro-inflammatory 
cytokines contribute to local and systemic inflammation, induce fever and 
anorexia, and are important for anti-influenza responses. IL-6 and TNF-α have 
been shown to carry out various effector functions, which restrict the extent of 
infection and the activation of adaptive immune response (Perrone, Szretter et al. 
2010, Dienz, Rud et al. 2012). IL-6 signaling helps to recruit neutrophils to the 
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lungs and protects the neutrophils from influenza virus-induced cell death (Dienz, 
Rud et al. 2012). Besides, IL-6 has been shown crucial for recall of influenza-
specific memory CD4
+
 T cells (Longhi, Wright et al. 2008). TNF-α has been 
shown to exert powerful anti-viral activity in lung epithelial cells (Seo and 
Webster 2002). By using KO mice model, another study demonstrates that 
influenza infection causes higher mortalities in IL-1β KO mice than in wild type 
(WT) mice (Kozak, Zheng et al. 1995), demonstrating the critical role of this 
cytokine in anti-influenza response.  
It has been reported in various studies that upon influenza virus infection, 
other than type-I IFNs and pro-inflammatory cytokines, large quantities of 
chemokines including macrophage inflammatory protein 1α (MIP-1α), RANTes, 
MIP-1β, IFN-γ inducible protein 10 (IP-10)) were detected in human, mouse and 
rat macrophages cell lines (Nain, Hinder et al. 1990, Hofmann, Sprenger et al. 
1997, Bussfeld, Kaufmann et al. 1998, Wareing, Lyon et al. 2004). These 
chemokines help to recruit large amount of leukocytes into the lung, which is 
important for control the infection. For instance, it has been shown that deficiency 
of MIP-1α in mice results in a delayed virus clearance (Cook 1996).  
Together, these studies demonstrated that early intervention by inflammatory 
cytokines and chemokines are critical for mounting a rapid and efficient immune 
response against influenza virus infection. 
1.5.10 Phagocytes 
Macrophages and neutrophils play critical roles in controlling early viral 
replication upon influenza virus infection. Depletion of either macrophages or 
 19 
neutrophils prior to a lethal infection with the 1918 HA/NA: Tx91 recombinant 
virus resulted in uncontrolled virus growth and mortality (Tumpey, Garcia-Sastre 
et al. 2005). However, depletion of these cell types 3 or 5 days P.I. did not alter 
disease outcome, indicating that macrophages and neutrophils act primarily to 
control viral replication during the early stages of infection (Kim, Lee et al. 2008). 
The mechanism of macrophages and neutrophils in controlling virus clearance 
during early infection seems to be phagocytosing the virus or infected cells, since 
the introduction of phagocytosis inhibitors into the airways of mice lead to 
increased lethality after influenza infection (Watanabe, Hashimoto et al. 2005). 
Influenza infection in macrophages is not productive as synthesis of viral proteins 
is halted midway and the macrophages undergo apoptosis before progeny virus 
can be released (Hofmann, Sprenger et al. 1997). On the other hand, once 
macrophages become activated, they produce, nitric oxide synthase 2 (NOS2) and 
TNF-α, which contributes to the influenza virus-induced lung pathology 
(Jayasekera, Vinuesa et al. 2006). Besides, during the early phase of influenza 
infection, macrophages produce various pro-inflammatory cytokines and 
chemokines to attract more innate immune cells to the lungs and type I IFNs to 
help to control the virus replication in the lungs, as we mentioned in the above 
section. 
1.5.11 Dendritic cells 
DCs, which are known as professional antigen-presenting cells in influenza 
virus infections, act as sentinels of the immune system. They are situated beneath 
the airway epithelium and monitor the airway lumen via their dendrites that are 
 20 
extended through the tight junctions between the airway epithelial cells. DCs can 
pick up antigens from infected and dying cells (Steinman and Hemmi 2006). They 
can be infected by influenza virus as well. Upon capturing antigen in the lung, the 
DCs then migrate to the lung draining lymph node, specifically to the posterior 
meditational lymph node where they present the influenza virus-derived antigens 
to naïve T cells to activate them (To, Hung et al. 2010, Ho, Prabhu et al. 2011). 
Moreover, DCs produce large amounts of type-I IFNs to increase the virus 
clearance ability of the body and increase the antigen presenting ability of DCs by 
promoting their maturation (Simmons, Wearsch et al. 2012).  
1.5.12 Natural Killer cells 
NK cells are key effector cells in innate immunity and play critical roles in 
host defense against influenza viruses by directly destroying virus-infected cells 
without initiating an adaptive immune response (Mao, Tu et al. 2009). They can 
also recognize antibody-bound influenza infected cells and lyse them through a 
process known as antibody-dependent cell cytotoxicity (ADCC) (Jegaskanda, Job 
et al. 2013). These cells can recognize influenza-infected cells by their receptors 
(NKp44, NKp46). Once binding to influenza HA, the receptors trigger the NK 
cells to lyse the infected cells (Arnon, Lev et al. 2001, Mandelboim, Lieberman et 
al. 2001). It has also been suggested that Natural killer T cells (NKT cells) induce 
cellular immunity and regulate infection-induced pathology (Paget, Ivanov et al. 
2011).  
1.5.13 Influenza induced signaling pathways in innate immune cells 
Upon recognition, influenza virus triggers a series of downstream signaling 
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in both macrophages and DCs, which lead to the expression of type-I IFNs, ISGs 
and pro-inflammatory cytokines to restrict the replication of influenza virus. 
TLR3, which recognizes virus-derived dsRNA in endosomes, expresses in 
lung epithelial cells and alveolar macrophages (Alexopoulou, Holt et al. 2001). As 
influenza virus-infected cells are not able to generate dsRNA (Pichlmair, Schulz 
et al. 2006), TLR3 senses influenza virus possibly by recognizing unidentified 
PAMPs that are present in phagocytosed dying influenza virus-infected cells (Le 
Goffic, Pothlichet et al. 2007). Upon activation, TLR3 triggers downstream 
signaling cascade via TIR-domain-containing adaptor-inducing IFN-β (TRIF). 
TRIF recruits receptor interacting protein 1 (RIP-1) before converging to TRAF 
activation. RIP-1 associates with TRAF3 to activate the Mitogen-Activated-
Protein Kinases (MAPKs), Nuclear factor κB (NF-κB), Tank binding kinase 1 
(TBK 1) and I-kappa-B kinase epsilon (IKKε). Activation of the NF-κB and 
MAPK pathways leads to the induction of cytokines and chemokines, which 
shape the nature, magnitude, and duration of host pro-inflammatory and innate 
immune responses (Gu, Ouyang et al. 2014). On the other hand, activated of 
TBK1 and IKKε phosphorylate IRF3, inducing the formation of IRF3 
homodimers which translocate from the cytoplasm into the nucleus. IRF3 in the 
nucleus binds IFN-sensitive response elements (ISREs) to regulate the 
transcription of type-I Ifns, IFN-stimulated genes (Isgs) and pro-inflammatory 





Figure 1. 7 TLR3, TLR7 and RIG-I induced type-I IFNs expression 
Influenza viruses can be recognized by PRRs including TLR3, TLR7 and RIG-I, which trigger 
MAPKs, NF-κB, IRF3 and IRF7 pathways. Phophorylated IRF3 and IRF7 form dimers and 
translocate from cytoplasm to nucleus to regulate type-I Ifns expression. 
 
The RNA helicase RIG-I expresses in lung epithelial cells, macrophages and 
DCs (Kolli, Velayutham et al. 2013). RIG-I, located in the cytosol, recognizes the 
5′-triphosphate viral ssRNA that is generated after viral replication in infected 
cells (Hornung, Ellegast et al. 2006, Pichlmair, Schulz et al. 2006, Baum, 
Sachidanandam et al. 2010, Rehwinkel, Tan et al. 2010) . Recognition of 
influenza viral RNA by RIG-I results in its binding to an adaptor protein known 
as mitochondrial antiviral-signaling protein (MAVS, also known as VISA, IPS-1 
and Cardif). MAVS induces downstream activation of TRAF-3 (Kawai, 
Takahashi et al. 2005), which leads to activation of MAPKs, NF-κB, TBK1 and 
IKKε to further regulate downstream pro-inflammatory cytokines, chemokines, 
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type-I IFNs and ISGs expression similar with downstream of TLR3 signaling as 
described above (Fig. 1.7). 
Expressed in mouse pDCs, TLR7 recognizes the ssRNA genomes contained 
within the influenza virions that are taken up into the endosome (Lund, 
Alexopoulou et al. 2004). This mode of recognition does not require viral 
replication. Upon TLR7 stimulation, MyD88 recruits IL-1 receptor-associated 
kinase (IRAK) through interaction of the death domains present in both molecules. 
IRAK is activated by phosphorylation and associates with TRAF6, which leads to 
the activation of interferon regulatory factor 7 (IRF-7), c-Jun N-terminal kinase 
(JNK) and NF-κB (Akira, Takeda et al. 2001). The activated IRF-7 translocates to 
the nucleus to regulate type-I IFNs and ISGs expression (Fig. 1.7). 
Recently, ssRNA and dsRNA were shown to activate the NLRP3 
inflammasome, and NLRP3 KO mice were reported to be more susceptible to 
influenza-associated morbidity and mortality (Allen, Scull et al. 2009, Thomas, 
Dash et al. 2009). The NLRP3 inflammasome is a multiprotein complex that 
activates caspase-1, leading to the secretion of pro-inflammatory cytokines 
interleukin-1β (IL-1β) and interleukin-18 (IL-18) (Tschopp and Schroder 
2010). NLRP3 expresses in several myeloid cell types, such as monocytes, DCs, 
neutrophils and macrophages. Several reports demonstrated that NLRP3 senses 
viral RNA and activates the inflammasome after influenza virus infection, which 
enhances the production of pro-inflammatory cytokines, especially IL-1β which 
plays an important role in the early responses to influenza infection (Allen, Scull 
et al. 2009, Thomas, Dash et al. 2009). 
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1.5.14 Evasion of influenza viruses from innate immune responses 
        Even though the hosts develop various stratgies to defense agasint influenza 
infection, the influenza virus adopted different strategies to evade the innate 
immunity system.  
        Paticularly, the NS1 is well known to antogonize the antiviral innate immune 
responses. It has been shown that NS1 inhibits type-I Ifns expression in animal 
models, cell lines and primary cells (Garcia-Sastre 2001). The inhibition of type-I 
Ifns expression is due to the formation of NS1-RIG-I complex, which blocks the 
recognition of 5’-ppp dsRNA by RIG-I. As such, the activation of IRF3 and 
production of type-I IFNs are greatly attenuated. Apart from NS1, both influenza 
PB2 and PB1-F limit type-I IFNs production through interaction with adaptor 
protein MAVS (Graef, Vreede et al. 2010, Varga, Ramos et al. 2011).  
        Additionally, influenza virus could also induce the 
expression of (suppressor of cytokine signaling) proteins to 
inhibit JAK/STAT activation through IFN α/β receptor signaling 
(Akhtar and Benveniste 2011). 
1.5.15 Transcription factor IRF3 in anti-viral response 
IRF3 is a member of the interferon regulatory transcription factor (IRF) 
family (Pitha, Au et al. 1998). IRF3 was originally discovered as 
a homolog of IRF1 and IRF2. IRF3 has been further characterized and shown to 
contain several functional domains including a nuclear export signal, a DNA-
binding domain (DBD), a C-terminal IRF association domain (IAD) and several 
regulatory phosphorylation sites (Yoneyama, Suhara et al. 2002).  In the rest state, 
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IRF3 is found as an inactive cytoplasmic form. Upon serine/threonine 
phosphorylation in response to viral infection, it forms a complex with CREBBP 
(Au, Moore et al. 1995). This complex translocates to the nucleus and activates 
the transcription of type-I Ifns, as well as other Isgs (Yoneyama, Suhara et al. 
1998). 
        IRF3 is activated in response to influenza virus infection and plays an 
important role in innate immune response to viral infection (Weaver, Kumar et al. 
1998). Aggregated MAVS and downstream proteins have been found to activate 
IRF3 dimerization (Lin, Heylbroeck et al. 1998). However, the activation of IRF3 
in response to influenza virus infection is inhibited by the influenza non-structural 
protein s (NS1). In the infected cell, NS1 interferes with the initial activation of 
the type-I IFNs signalling cascade by preventing recognition of the viral ssRNA 
by RIG-I (Pichlmair, Schulz et al. 2006). 
The regulation of IRF3 signaling is complicated. In the recent years, a large 
number of groups work on this signaling pathway and made notable progress in 
understanding the mechanism of IRF3 activation and deactivation. For example, 
Melanoma Differentiation-Associated protein 5 (Mda5), which is another well-
known PRR that belongs to RIG-I like Receptors (RLRs) family, can sense 
dsRNA that is over 2000 necleotides (nts) in length from various viruses, but not 
influenza viruses, triggering IRF3 mediated anti-viral responses (Kato, Takeuchi 
et al. 2008). Other PRRs such as NOD-like receptor family CARD domain 
containing 5 (NLRC5) and NLRP4 have been shown to negatively regulate IRF3 
mediated type-I IFNs expression by inhibiting RIG-I and Mda5 function or 
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targeting TBK1 for degradation respectively (Cui, Zhu et al. 2010, Cui, Li et al. 
2012). Moreover, a study demonstrated that microtubule-associated guanine 
nucleotide exchange factor GEF-H1 positively controls microtubule-dependent 
sensing of nucleic acids for IRF3 mediated anti-viral host defenses (Chiang, Zhao 
et al. 2014). Other studies also revealed that the cytosolic nucleic acid sensor 
LRRFIP1 and another RLR LGP2 are involved in the regulation of type-I IFNs 
production (Yang, An et al. 2010, Malur, Gale et al. 2012). These findings shed 
lights on the importance of viral recognition in the induction of IRF3 activation. 
IRF3 is well known to be phosphorylated by the upstream kinases including 
TBK1 and IKKε. Apart from the activation of IRF3 by kinases, negative 
regulation of IRF3 by phosphatases attracts considerable attention recently. A 
phosphatase known as protein phosphatase 2 (PP2A) has been shown contribute 
to the termination of IRF3 mediated type-I IFNs signaling together with its 
adaptor protein RACK1 by directly dephosphorylating activated IRF3 (Long, 
Deng et al. 2014). Another group of phosphatases, the MAPK phosphatases 
(MKPs), have been implicated in inhibiting IRF3 signaling possibly through 
enhancing the formation of MKPs-IRF3-TBK1 complex in response to bacterial 
infection (Negishi, Matsuki et al. 2013). However, the mechanism of IRF3 
inactivation by dephosphorylation is not fully understood. Further studies are 
needed to elucidate the negative regulation of this important protein in response to 
virus infection. 
        MAPKs have been reported to be involved in IRF3 activation and anti-viral 
response by using specific MAPKs inhibitors. Navarro and David demonstrated 
 27 
that inhibition of p38 activation by SB203580 inhibited the expression of type-I 
Ifns and Isgs expression in response to Lipopolysaccharide (LPS) stimulation in 
macrophage cell lines (Navarro and David 1999). JNK activation was later found 
to be required for IRF3 activation in response to both LPS and poly (I: C) 
stimulation (Zhang, Li et al. 2009). Wang, Ma et al. demonstrated that ERK 
inhibition in epithelial cells inhibit IRF3 mediated type-I IFNs expression in 
response to myxoma virus infection (Wang, Ma et al. 2004). These studies 
prompted the involvement of MAPKs in the regulation of IRF3 mediated type-I 
IFNs expression in addition to the regulation of other pro-inflammatory cytokines 
including IL-6 and TNF-α expression. 
        Previously, MKP-2 has been shown to negatively regulate IFN-β promoter 
acitivity in response to LPS and poly (I: C) stimulation in macrophages cell line 
(McCoy, Carpenter et al. 2008). Nevertheless, the function of MKP-2 in anti-viral 
function is still not well characterized. Based on previous results that MKP-2 
negatively regulates pro-inflammatory cytokines expression and IFN-β promoter 
activity (McCoy, Carpenter et al. 2008), we hypothesized that MKP-2 plays 
critical roles in innate immune response to influenza infection. We therefore 
looked into the regulatory role of MKP-2 in innate immune response to influenza 
infection.   
1.5.16 Specific aims of this study 
        While some studies have briefly examined the role of MKP-2 in intracellular 
parasitic infections, the immunomodulatory roles of this protein in virus 
infections remain poorly understood. Particularly, there is not much information 
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so far on the role of MKP-2 in regulating the innate immune response to influenza 
virus infection. In the present study, we sought to examine the function of MKP-2 
in influenza infection with the hope to identify novel mechanism underlying a 
more effective immune response to influenza infection. 
Specific aims of the study: 
1. Investigate the in vivo role of MKP-2 in immune response to influenza virus 
infection using WT and MKP-2 KO mice. 
2. Investigate the regulation of type-I IFNs and other pro-inflammatory cytokines 
expression by MKP-2 upon influenza virus infection in vivo and in vitro. 
3. Elucidate the role of MKP-2 in regulating type-I IFNs and other pro-
inflammatory cytokines expression upon various PRRs activation. 
1.6 Macrophage-adipocyte co-culture model 
1.6.1 Insulin resistance and metabolic disorders 
Obesity is rapidly emerging as a major public health issue worldwide which is 
associated with an increased risk of insulin resistance and Type 2 Diabetes (Kahn, 
Hull et al. 2006). In 2004, an estimated 3.4 million people died from 
consequences of fasting high blood sugar. A similar number of deaths have been 
estimated for 2010 (WHO 2013).  
The metabolic syndrome is a cluster of metabolic abnormalities including 
glucose intolerance, overt hyperglycemia, hyperinsulinemia, and atherogenic 
dyslipidemia leading to increased risk for cardiovascular diseases and type 2 
diabetes (Fulop, Tessier et al. 2006). Insulin is a hormone, which plays a key role 
in the regulation of blood glucose homeostasis by stimulating glucose uptake 
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mainly in adipose tissue and skeletal muscle and reducing hepatic glucose 
production via gluconeogenesis and glycogenolysis (Rains and Jain 2011). IR is a 
state where the body fails to respond appropriately to insulin (Bastard, Maachi et 
al. 2006, Tilg and Moschen 2008). Hence, in the body IR decreases glucose 
uptake in skeletal muscles, increases hepatic gluconeogenesis and β cells 
dysfunction, leading to hyperglycemia and hyperinsulinemia. Therefore, IR and 
obesity have long been considered as the most pivotal components in the 
pathogenesis of metabolic syndromes (Park, Zaichenko et al. 2013). 
1.6.2 Adipose tissue inflammation and insulin resistance 
Obesity associated inflammation in adipose tissue is critical in the initiation 
and progression of systemic insulin resistance by impacting other metabolic 
organs including skeletal muscle and liver (Neels and Olefsky 2006, Balistreri, 
Caruso et al. 2010). Various mediators synthesized by adipocytes and adipose 
tissue macropahges (ATMs) contribute to adipose tissue chronic inflammation. 
1.6.3 Macrophages 
Macrophages are the major immune cells, which infiltrate in adipose tissue 
in response to high-fat diet (HFD) in mice (Strissel, DeFuria et al. 2010). ATMs 
are a prominent source of pro-inflammatory cytokines such as TNF-α, IL-6 and 
IL-1β that can block insulin action in adipocytes (Wen, Gris et al. , Stephens, Lee 
et al. 1997, Rotter, Nagaev et al. 2003). Therefore, macrophage infiltration into 
the expanding adipose tissue plays a key role in causing inflammation and linking 
obesity to insulin resistance (Sell, Habich et al. 2012). In the lean insulin sensitive 
state, ATMs are polarized toward an M2 state with IL-10 and arginase expression. 
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During the HFD-induced progressive obesity, ATMs undergo a phenotypic switch 
from an anti-inflammatory M2 polarization to a pro-inflammatory M1 
polarization state in the process of losing their protective capacity in keeping 
insulin sensitivity (Fig. 1.8) (Lumeng, Bodzin et al. 2007). M1 or “classically 
activated” macrophages are induced in vitro by pro-inflammatory mediators such 
as IFN-γ and LPS (Krausgruber, Blazek et al.). M1 macrophages produce pro-
inflammatory cytokines, such as TNF-α, IL-6, IL-12 and MCP-1, thus 
contributing to the induction of insulin resistance (Gordon 2003, Mantovani, Sica 
et al. 2004, Gordon and Taylor 2005). M2 or “alternatively activated” 
macrophages are generated in vitro by exposure to IL-4 and IL-13 (Gordon and 
Martinez , Lumeng, Bodzin et al. 2007). M2 macrophages, on the other hand 
express high levels of M2 markers including arginase-1 (Arg-1), Chi3l3 (Ym-1), 
Mgl1 and IL-10 (Ohashi, Parker et al. 2010). In addition to the macrophages, 
other immune cells including T cells, eosinophils, B cells et al. also infiltrate to 
obesity-expanded adipose tissue. These infiltrated immune cells dictate the extent 
of local inflammatory response by modulating macrophages polarization through 






Figure 1. 8 Proposed model for ATM polarization and its function in adipose tissue with 
progressive obesity adapted from (Lumeng, Bodzin et al. 2007) 
In lean, insulin-sensitive states, ATMs are M2-like macrophages state with high expression of IL-
10 and arginase. Upon HFD treatment, hypertrophied adipocytes release chemokines that induce 
recruitment of M1-like ATMs with low expression of IL-10 and high expression of iNOS and 
TNF-α. In this stage, the M2-like ATMs are able to partially protect adipocytes from the 
development of insulin resistance. In the severe state, more M1-likes ATMs are recruited to 
adipose tissue to form crownlike structures (CLS) leading to high expression of TNF-α and iNOS, 
which generate insulin resistance in adipocytes. 
 
1.6.4 Adipocytes 
Adipocytes are known to secrete hormones, cytokines, and FFAs, most of 
which have been shown to play some roles in inflammation and systemic insulin 
resistance (Xu, Barnes et al. 2003). There is crosstalk between macrophages and 
adipocytes during the HFD induced progressive insulin resistance. When the 
adiposity of the adipocytes reaches a certain threshold, the adipocytes will 
produce several factors including chemokine MCP-1 and FFAs to induce 
macrophage infiltration and activation. Activated macrophages secrete cytokines 
to impair insulin sensitivity in adipocytes and triggers lipolysis of adipocytes to 
release more FFAs (Xu, Barnes et al. 2003). The released FFAs can further 
circulate to other tissues and organs to induce systemic insulin resistance (Zhai, 
Xu et al. 2010). A recent report demonstrated that co-culture of adipocytes and 
macrophages in vitro aggravates inflammatory changes with increased TNF-α 
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production and FFAs secretion (Suganami, Nishida et al. 2005). Therefore, 
nowadays people tend to accept that a complex crosstalk among adipocytes, 
macrophages and other immune cells contributes to adipose tissue inflammation 
and insulin resistance (Sun, Kusminski et al. 2011). 
1.6.5 Adipose tissue factors involved in insulin resistance 
TNF-α is a major pro-inflammatory cytokine, which contributes to the 
development of adipose tissue insulin resistance (Sethi and Hotamisligil 1999). 
Neutralization of TNF-α showed increased insulin sensitivity in obese rats, which 
provides evidence that TNF-α induces insulin resistance in rats (Cheung, Wang et 
al. 2000). Furthermore, TNF-α also triggers lipolysis of adipocytes to release 
FFAs so that it can induce insulin resistance in other organs apart from adipose 
tissue (Zhang, Halbleib et al. 2002) 
FFAs are another key factor that triggers adipose tissue insulin resistance 
(Qatanani and Lazar 2007). Obese individuals have chronically raised FFAs levels 
which have been shown to affect the insulin signaling pathway in skeletal muscles 
to decrease the glucose transport (Boden and Shulman 2002). FFAs also 
contribute to insulin resistance by impairing muscle glucose uptake via 
competitive inhibition. In liver, raised FFAs can stimulate endogenous glucose 
production, thus contributing to hepatic insulin resistance (Boden and Shulman 
2002). In addition, FFAs are also able to activate macrophages to produce 
cytokines including TNF-α and IL-1β which contribute to the development of 
insulin resistance through TLR4 pathway (Suganami, Nishida et al. 2005, Shi, 
Kokoeva et al. 2006, Wen, Gris et al. 2011).  
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Other factors including adiponectin, leptin and resistin are also involved in 
the regulation of adipose tissue insulin resistance. For example, adiponectin is a 
circulating protein produced by adipose tissue that has anti-inflammatory 
properties, which increases insulin sensitivity whereas resistin, another circulating 
factor in adipose tissues, reduces insulin sensitivity (Steppan, Bailey et al. 2001, 
Holst and Grimaldi 2002). Leptin is well known to inhibit food intake, reduces 
body weight and stimulates energy expenditure (Trayhurn, Hoggard et al. 1999). 
Leptin deficient mice are broadly used as a spontaneous obesity and insulin 
resistant mice model worldwide.  
 
1.6.6 MAPKs in metabolism 
MAPKs are evolutionarily conserved regulators that mediate signal 
transduction and play essential roles in various physiological processes (Zhang 
and Dong 2007). There are three major MAPKs namely the ERKs, JNKs and the 
p38 MAPKs (Qi and Elion 2005). (Refer to section 1.5). 
Many studies have causally implicated MAPKs in the development of insulin 
resistance (Gehart, Kumpf et al. 2010). For instance, JNK activity has been shown 
to be elevated following a HFD in mice. Global deletion of JNK1 or its specific 
deletion in adipose tissue, skeletal muscle and brain has been shown to attenuate 
diet-induced insulin resistance in mice (Sabio and Davis , Hirosumi, Tuncman et 
al. 2002), which indicate that JNK1 activation promotes diet induced insulin 
resistance. p38 MAPK phosphorylation is markedly reduced in the liver, muscle 
and adipose tissues of ob/ob and HFD-fed obese mice (Lee, Sun et al.). Activation 
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of p38 in liver can help to maintain glucose homeostasis (Lee, Sun et al.), which 
suggests an opposing role compared with JNK1 in the regulation of insulin 
sensitivity. ERK1 is required in the early steps of adipogenesis. Similar to JNK1, 
ERK1 KO mice are protected from diet-induced obesity and insulin resistance (M, 
Moro et al. 2006). Although all the MAPKs have been demonstrsted to be 
involved in metabolic processes, the pathophysiological consequence of altered 
MAPK activity in metabolic syndrome still remains to be fully defined.  
1.6.7 MKPs in metabolism 
MAPK phosphatases (MKPs) or dual specificity phosphatases (DUSPs) have 
been defined as major negative regulators of MAPKs (Zhang and Dong 2007). 
Using gene KO mice, MKP-5, MKP-1 and MKP-2 were found to be important 
negative regulators of inflammatory cytokine production in innate immune 
responses whereas PAC-1 has been found to positively regulate inflammatory 
cytokine production in innate immune responses (Al-Mutairi, Cadalbert et al. , 
Cornell, Rodenhouse et al. , Chi, Barry et al. 2006, Jeffrey, Brummer et al. 2006, 
Zhang, Reynolds et al. 2009). Therefore, by regulating inflammatory cytokine 
production, these MKPs are expected to play important roles in the development 
of insulin resistance in the body. 
Indeed, several MKPs have been shown to regulate systemic insulin 
sensitivity and glucose homeostasis. For instance, mice lacking MKP-1 have been 
reported to be resistant to diet-induced obesity due to enhanced energy 
expenditure (Wu, Roth et al. 2006). MKP-4 has been shown to play a potential 
role in promoting insulin resistance by inhibiting insulin-stimulated glucose 
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uptake and stressed-induced insulin resistance in adipocytes (Xu, Dembski et al. 
2003, Emanuelli, Eberle et al. 2008). Mice deficient in MKP-3 have been shown 
to be resistant to diet-induced obesity and systemic insulin resistance (Feng, Jiao 
et al. 2014). Taken together, these findings suggest the involvement of MKPs in 
the regulation of metabolic disease.  
1.6.8 Specific aims of this study 
While some studies have examined briefly the role of MKP-2 in the regulation 
of pro-inflammatory cytokines production in innate immune response to LPS 
stimulation, there is no data so far on the role of MKP-2 in regulating chronic 
inflammation during adipocyte-macrophage interaction. In the present study we 
sought to examine the role of MKP-2 in inflammation during adipocyte-
macrophage interaction, which could provide information on the possible role of 
MKP-2 in regulation of metabolic disease. 
Specific Aims of the study: 
1. Characterize the role of MKP-2 in the regulation of inflammatory cytokine 
expression in macrophages in response to FFAs stimulation. 
2. Determine the role of MKP-2 in the regulation of inflammation during 
adipocyte-macrophage interaction. 






Chapter 2 Materials and Methods 
2.1 Culture of Cell Lines  
 EMEM medium (Lonza) supplemented with 10% heat inactivated Fetal 
Bovine Serum (FBS) (Invitrogen, USA) and 1% Penicillin/Streptomycin mixture 
(Invitrogen, USA) was used to culture Madin-Darby Canine Kidney (MDCK) 
cells (ATCC, obtained from Chow V.T.K., NUS). Similarly, RPMI-1640 medium 
(Gibco) and DMEM medium (Gibco) supplemented with 10% heat-inactivated 
FBS (Invitrogen, USA) and 1% Penicillin/Streptomycin (Invitrogen, USA) were 
used to culture RAW264.7 cells and HEK293T cells respectively. 3T3-L1 
preadipocytes were maintained in DMEM (Invitrogen) containing 10% Bovine 
serum (Invitrogen), 1% Pen/Strep (Invitrogen) and supplemented with 1 mM 
sodium pyruvate (Invitrogen). All the cells were all incubated at 37 °C in a 
humidified 5% CO2/95% air atmosphere. Differentiation of 3T3-L1 preadipocytes 
to mature adipocytes was performed using insulin (Sigma), dexamethasone 
(Sigma) and 3-isobutyl-1-methly-xanthine (Sigma) as described by Yamashita, 
Soga et al. (Yamashita, Soga et al. 2008) and used as differentiated 3T3-L1 
adipocytes at day 8 after the induction of differentiation. The M1 activation was 
induced by culturing RAW264.7 in the presence of 20 ng/mL mouse recombinant 
IFN-γ (BD Pharmingen) for 12 h followed by 100 ng/mL LPS (Sigma) 
stimulation for another 12 h. M2 activation of RAW264.7 cells was induced by 20 
ng/mL IL-4 (Biolegend) or 20 ng/mL IL-13 (Biolegend) for 12 h. Palmitate-BSA 
(Sigma) complex preparation was performed as described (Shi, Kokoeva et al. 
2006). Palmitate was dissolved in 95% ethanol at 60°C and then was mixed with 
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prewarmed 10% FFAs-free BSA (Sigma) to yield a stock concentration of 7.5 
mM.  
2.2 Plasmids 
IFN-β promoter luciferase reporter plasmid was a gift from Prof. Krishman 
M.N., Duke-NUS. AP-1 promoter luciferase reporter plasmid was a gift from 
Prof. Dong Chen M. D. Anderson Cancer Center, Houston, Texas. HA-VISA, 
HA-TBK1 and HA-IKKε expressing plasmids were gifts from Prof. Shu 
Hongbing, Wuhan University. Flag-tagged MKP-2, pcDNA3.1-MKP-2 and HA-
tagged IRF3 were constructed by standard molecular biology techniques.  
2.3 Buffers 
 
Table 2. 1 Amonium-Chloride-Potassium (ACK) buffer 
Components Concentrations (mg/L) mM 
Ammonium Chloride (Sigma-Aldrich) 8290 154.95328 
Potassium Bicarbonate (Sigma-Aldrich) 1000 9.99001 
EDTA (Sigma-Aldrich) 37 0.09946237 
 
Table 2. 2 Tail lysis buffer 
Components Concentrations 
Tris (Sigma-Aldrich) buffer pH 8.0-8.5 100 mM 
EDTA (Sigma-Aldrich) 5 mM 
SDS (Sigma-Aldrich) 0.2% 
NaCl (Sigma-Aldrich) 200 mM 
 
Table 2. 3 NP40 protein lysis buffer 
Components Concentrations 
Tris (Sigma-Aldrich) buffer pH 7.8 50 mM 
NaCl (Sigma-Aldrich) 150 mM 
NP40 (Sigma-Aldrich) 1% 
 
 38 
Table 2. 4 4× protein loading buffer 
Components Concentrations 
Glycerol (Sigma-Aldrich) 46% 
SDS (Sigma-Aldrich) 8% 
Tris  (Sigma-Aldrich)buffer pH 6.8 250 mM 
β-mercaptoethanol (Sigma-Aldrich) 2% 
Bromophenol (Sigma-Aldrich) A bit 
 
Table 2. 5 protein stripping buffer 
Components Concentrations 
Glycine (Sigma-Aldrich)pH 2.5 20 mM 
Tween-20 (Sigma-Aldrich) 0.05% 
 
Table 2. 6 Tris-Buffered Saline and Tween-20 (TBST) washing buffer 
Components Concentrations 
Tris (Sigma-Aldrich) buffer pH 7.6 20 mM 
Tween-20 (Sigma-Aldrich) 0.05% 
NaCl (Sigma-Aldrich) 137 mM 
 
Table 2. 7 10× SDS running buffer 
Components Concentrations 
Glycine (Sigma-Aldrich) 192 mM 
Trizma Base (Sigma-Aldrich) 25 mM 
SDS (Sigma-Aldrich) 1% 
 
Table 2. 8 10× transfer buffer 
Components Concentrations 
Glycine (Sigma-Aldrich) 192 mM 
Trizma Base (Sigma-Aldrich) 25 mM 
 
2.4 Animals 
Approval for the animal study was obtained from the Institutional Animal 
Care and Use Committee of National University of Singapore under the protocol 
number 092/10. Inbred C57BL/6 MKP-2 KO mice were generated under the 
breeding protocol BR25/10. Only mice aged between 9 – 15 weeks old were used 
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in the experiments. 
0.5 cm of new weaned mice tails were cut off to isolate genomic DNA. The 
tail was lysed in 0.5 mL tail lysis buffer supplemented with 100 μg/mL Proteinase 
K (Sigma-Aldrich) at 55℃ in the heat block with shaking overnight. After 
digestion, the supernatant was spinned down and transferred to a new eppendorf 
tube. The DNA in the supernatant was precipitated with 1 mL 100% ethanol 
(Sigma-Aldrich) and washed with 1 mL 70% ethanol. The genomic DNA pellet 
was dissolved in 100 μL TE buffer (Invitrogen). Polymerase Chain Reaction 
(PCR) was carried out using 2 μL of the DNA as template. 
Genotyping of the MKP-2 KO mice was done according to the protocol 
provided by Welcome Trust Sanger Institute listed below: 
Table 2. 9 PCRs primer pairs and expected size band 
PCR type Forward primer Reverse primer Expected size band (bp) 
Mutant PCR Dusp4_40321_F CAS_R1_Term x 321 
WT PCR Dusp4_40321_F Dusp4_40321_R 441 
LacZ PCR LacZ_2_small_F LacZ_2_small_R 108 
 
Table 2. 10 Primer sequences 
Primer name Primer sequence (5’>3’) 











Table 2. 11 PCR Reaction 
Reagent Μl 
DNA (~50-100ng) 1.0 
10×buffer (i-DNA biotechnology) 2.0 
dNTP (100mM) (Promega) 0.4 
Primer 1 (10μM) 0.4 
Primer 2 (10μM) 0.4 
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Table 2. 12 Cycling conditions 
WT and mutant PCRs LacZ PCR 
Cycle Cycle 
1  94℃  5 min 1  94℃  5 min 
2  94℃  30 sec 2  94℃  30 sec 
3  58℃  30 sec 3  60℃  30 sec 
4  72℃  45 sec 4  72℃  30 sec 
5  Go to ‘2’ + 31 cycles 5  Go to ‘2’ + 31 cycles 
6  72℃  5 min 6  72℃  5 min 
7  12℃  forever 7  12℃  forever 
 
Table 2. 13 Genotyping results prediction 
WT WT positive, mutant negative, LacZ negative 
Heterozygous WT positive, mutant positive, LacZ positive 
KO WT negative, mutant positive, LacZ positive 
     
        All the primers used in this study were synthesized by Integrated DNA 
Technologies (IDT).  
        WT mice were fed with normal chow or HFD after weaning for 8 weeks. The 
White adipose tissue (WAT) from the mice were isolated and homogenized in 500 
μL Trizol® (Invitrogen, USA) using the Bullet Blander (Next Advance, USA), 
followed by mRNA extraction. Stromal vascylar fractions (SVFs) from the WATs 
were isolated to examine MKP-2 expression. 
2.5 Infection of animals and tissues processing 
        Anesthetizing of the mice was done via intra-peritoneal injection of ketamine 
(Parnell, Australia) and medotomidine (Pfizer, Singapore) at 0.75 mg and 0.01 mg 
per 10 g of body weight respectively prior to the infection procedure. 50 or 500 
pfu of PR8 virus was diluted to 100 µl of sterile Phosphate Buffered Saline (PBS) 
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(1st Base, Singapore). The virus suspension was used to infect the mice via the 
intranasal route in supine position. This route of infection ensured that all mice 
received an identical dose of virus through total uptake of fluids into the lungs. 
The effects of anesthesia were reversed after infection through the administration 
of atipamezole (Pfizer, Singapore) at 0.001 mg per 10 g of body weight. Disease 
progression was monitored daily by weighing the mice and the mice were 
sacrificed on day 2, 3, 5 and 11 by CO2 gas asphyxiation. 
        In order to process the tissue, firstly the lung cavity and trachea of the mice 
was dissected. The lung was washed twice with 700 µl of PBS to obtain the 
Bronchoalveolar lavage (BAL) fluid, which was then stored at -80oC for ELISA 
analysis (section 2.15). The lungs harvested from the mice were used for 3 
separate experiments: gene expression analysis (section 2.14), viral loads analysis 
(section 2.13) and leukocytes population analysis (section 2.18). Firstly, the same 
pieces of lungs from different mice was homogenized in 500 μL Trizol® 
(Invitrogen, USA) using the Bullet Blander (Next Advance, USA) and followed 
by mRNA extraction (section 2.14). Secondly, the same pieces of lungs from 
different mice was homogenized in 500 μL PBS and stored at -80 °C for viral load 
determination (section 2.13). The remaining lung tissue was then minced up and 
digested into single cells suspension with 1 mg/mL collagenase (Roche, USA) for 
90 min at 37℃. The cells suspension was then filtered through 70 μm cells 
strainers (BD biosciences) and ACK lysis buffer was added to it. The cell 
suspension was rested for 3 min for the lysis of red blood cells. Next, leukocyte 
separating medium (Lonza, USA) was used to isolate the leukocytes through 
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centrifugation at a speed of 2000 rpm, for 20 minutes. The leukocytes, which are 
the cells in the inter-phase, were taken out and subsequently used for 
immunostaining for flow cytometry analysis (section 2.18). 
2.6 Isolation procedure of Bone Marrow Derived Macrophages (BMDMs) 
and Bone Marrow Derived Dendritic Cells (BMDCs) 
        BMDMs and BMDCs were cultured from bone marrow cells of C57BL/6 
mice.  
        For isolation of BMDMs, the femurs and tibias harvested from the mice were 
flushed with sterile PBS using a 27G×1
1/4 needle (PrecisionGlide
® Needle, USA), 
after which the cells obtained were broken down into single cells using an 
18G×1
1/2 needle (TERUMO
® Needle). The cells were then filtered through a 70 
μm cell strainer (BD Biosciences, USA) and any red blood cells present were 
lysed using ACK lysis buffer. Trypan blue assay (Life Technologies) was used to 
perform viable cell count. Cells were resuspended in complete RPMI media 
supplemented with 20 ng/ml of macrophage colony-stimulating factor (M-CSF; 
PeproTech, USA). 5x106 bone marrow cells per 10 ml of M-CSF supplemented 
RPMI were plated in sterile Petri dishes (100 x 15 mm; Fish scientific, USA) and 
cultured in a humidified 37 oC incubator with 5% CO2. On day 2, 4 and 6, 10 ml 
of fresh RPMI medium supplemented with 20 ng/ml M-CSF was added to the cell 
cultures. On Day 7, the macrophages were stained for APC-CD11b (eBiosciences) 
positivity (section 2.18). Macrophages with > 90% CD11b purity were then 
seeded in 6 or 12-well plates for subsequent experiments. 
In order to culture BMDCs, 5x106 bone marrow cells per 10 ml of GM-
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CSF (PeproTech, USA) supplemented RPMI were plated in sterile Petri dishes 
(100 x 15 mm; Fish scientific, USA) and cultured in a humidified 37 oC incubator 
with 5% CO2. On day 2, 4, 6 and 8, 10ml of fresh RPMI medium supplemented 
with 20 ng/ml GM-CSF was added to the cell cultures. On day 9, the DCs were 
stained for APC-CD11c (eBiosciences) positivity (section 2.18). DCs with > 90% 
CD11c purity were then seeded in 6 or 12-well plates for subsequent experiments. 
2.7 SVFs preparation from the white adipose tissue 
        Epididymal fat pads from male C57BL/6 mice fed an normal chow (NC) 
were excised and minced in PBS (1st base, Singapore) with calcium chloride 
(Sigma-Aldrich) and 0.5% BSA (Sigma-Aldrich). Tissue suspensions were 
centrifuged at 500 g for 5 min to remove erythrocytes and free leukocytes. 
Collagenase (Sigma-Aldrich) was added to 1 mg/ml and incubated at 37 °C for 20 
min with shaking. The cell suspension was filtered through a 100-μm filter and 
then spun at 300 g for 5 min to separate floating adipocytes from the SVF pellet. 
2.8 In vitro infection procedure 
For infection of BMDMs, 1.5 million cells per well were seeded in 12 well 
plates for quantitative Real-Time PCR (qRT-PCR) and ELISA analysis and cells 
were seeded into 6 well plates with 5 million cells per well for western blot 
analysis. All the cells were seeded in complete RPMI 1640 media and allowed to 
rest overnight. The following day, PR8/34 virus at a MOI of 1 was added into the 
wells. For qRT-PCR analysis (refer to Section 2.14), samples were harvested 
using Trizol
®
 (Invitrogen) 6 hours post infection. For ELISA cytokine analysis 
(refer Section 2.15), supernatant from control or infected wells were collected 24 
h post infection. For western blot analysis (refer Section 2.16), whole cell lysates 
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were harvested 0, 1, 3, and 6 hours after infection. 
        Similar to BMDMs, BMDCs infection was done in 12 well plates with 1.5 
million cells per well (for qRT-PCR analysis) and ELISA analysis. After resting 
overnight, PR8/34 viruses were added into the wells at a MOI of 1. For qRT-PCR 
analysis (refer to Section 2.14), samples were harvested using Trizol® (Invitrogen) 
6 hours post infection and for ELISA cytokines analysis (refer Section 2.15), 
supernatants from control or infected wells were collected 24h after incubation. 
2.9 In vitro stimulation  
BMDMs were seeded in 12 well plates with 1.5 million cells per well (for 
qRT-PCR and ELISA analysis) and 6 well plates with 5 million cells per well (for 
western blot analysis). The cells were rested overnight and were transfected the 
following day with either poly (I:C) (0.5 µg/mL) (Sigma, Aldrich) or 5’-ppp 
dsRNA (0.5 µg/mL) (Invivogen) using Lipofectamine LTX reagent (Invitrogen) 
(refer to Section 2.11). . The whole cell lysates were harvested for western blot 
analysis 1, 3 and 6 h after transfection. Samples were harvested for qRT-PCR 
analysis 6 h after transfection while the supernatants were harvested for ELISA 
analysis 24 h after transfection. 
For stimulation of BMDCs, cells were seeded in 12 well plates with 1.5 
million cells per well (for qRT-PCR and ELISA analysis) in complete RPMI 1640 
media. After resting overnight, R848 (100 ng/mL) (InvivoGen) was added into 
the wells for incubation. 6 and 24h after stimulation, the supernatants was 
harvested for ELISA analysis. 6 h after transfection, samples were harvested 
using Trizol
®
 (Invitrogen) for qRT-PCR analysis. 
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2.10 ERK, JNK and p38 inhibition 
For ERK inhibition, the BMDMs or BMDCs were pretreated with ERK 
inhibitor PD98059 (100 µM) (Sigma, Aldrich) or DMSO (Sigma, Aldrich) as 
vehicle control for 1 h before infection. After pretreatment, the cells were infected 
with PR8 (MOI: 1) in the presence of PD98059 (100 µM) or DMSO as vehicle 
control for indicated time-points before harvesting. 
For JNK and p38 inhibition, the RAW264.7 cells were pretreated with JNK 
inhibitor SP100625 (20 µM) (Sigma) or p38 inhibitor SB23580 (20 µM) (Sigma) 
for 1 h before M1 activation. After pretreatment, the cells were stimulated with 
M1 activators in the presence of SP100625 (20 µM) or p38 inhibitor SB23580 (20 
µM) PD98059 for indicated time points. DMSO was used as vehicle control. 
2.11 Transfection procedure by transfection reagents 
293T cells transfection was done by using TransIT®-293 Transfection 
Reagent (Mirus Bio LLC). 2.5 µg (2.5 µl of a 1 µg/µl stock) plasmid DNA was 
placed in 250 µl of Opti-MEM (Gibco, USA) in a sterile tube. 7.5 µl TransIT-293 
reagents were added to the diluted DNA mixture gently pipetted and incubated at 
room temperature for 15–30 min. After incubation, the TransIT-293 Reagent: 
DNA complexes were added to the cells drop-wise and the cells were rested in the 
incubator for 16-24 h before harvesting. 
       Transfection of BMDMs was done using Lipofectamine LTX Reagent 
(Invitrogen). 1.2 µg of DNA was placed in 160 µl of Opti-MEM (Gibco, USA) in 
a sterile tube and 1.5 µl PLUS Reagent (Invitrogen) was added to the diluted 
DNA mixture. After 5-10 min of incubation, 7.5 µl LTX Reagent (Invitrogen) was 
added to the complex mixture and further incubated at room temperature for 30 
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min after which the reagent: DNA complexes were added to the cells drop-wise. 
2.12 Virus propagation 
Propagation of the mouse adapted Strain A/Puerto Rico/8/1934 H1N1 (PR8) 
virus (obtained from Chow V.T.K., NUS) was done by cultivation of the virus in 
allantoic cavities of 10 to 11-day old fertilized eggs for 72 h (Balish, Katz et al. 
2013). The Specific-Pathogen-Free (SPF) embryonated chicken eggs were 
candled for a spot in the allantoic cavity and a small slit was drilled on this spot 
over the chorioallantoic membrane using an 18G×1
1/2 needle (TERUMO
® 
Needle). The virus was diluted 1:100 in sterile PBS and 200 μl of the viral 
dilution was placed in the allantoic cavity through the slit using a 27G×1
1/4 needle 
(PrecisionGlide® Needle, USA). The slits were sealed with melted candle wax and 
the eggs were incubated in a 37oC incubator (with water tray for humidification) 
for 2 to 3 days. The eggs were turned manually twice a day and candled daily to 
check for death of the chicken embryo. On Day 3, the eggs were chilled in the 
refrigerator for 2 h and then in a -20 oC freezer for 1 h to kill the embryo and 
prevent bleeding. The shell is swabbed with 70% alcohol and broken from the air 
sac after which the membranes were ruptured with a broad-tipped pipette and the 
allantoic fluid was aspirated. The fluid was centrifuged at 3800 rpm for 15 min. 
The viral supernatant was filtered through 0.04 μm filter and aliquoted into 1 ml 
cryovials and stored at -80 oC before usage. The titer of the virus stock was 
measured by plaque assay (section 2.13). 
2.13 Plaque assay 
The viral loads per unit mass (pfu/mg) in the homogenized mouse lung tissue 
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samples were determined using the modified plaque assay (Matrosovich, 
Matrosovich et al. 2006). Briefly, MDCK cells were seeded at 2.0 x 105 per well 
in 24-well plates and incubated overnight to ensure monolayer growth of MDCK 
cells. The following day, infected homogenized lung tissue samples or viruses 
stocks were serially diluted (101, 102, 103, 104, 105, and 106) in serum-free EMEM 
culture medium (Lonza, USA) containing 1 µg/ml TPCK-treated trypsin (Sigma, 
USA) and 250 µl of the inoculum was added into each separate well and 
incubated at 37oC in 5% CO2 for 1 h. The infected cells were washed with PBS 
for 3 times. Next a 1.2% Avicel (FMC Biopolymer, USA) overlay was prepared in 
EMEM and added to the wells. The plates were incubated at 37oC in 5% CO2 for 
60-70 h before fixing the cells with 8% formaldehyde (Merck, Germany) and 
staining with crystal violet dye (Sigma, USA). The lowest dilution with distinct 
plaque formation was counted to determine the viral loads in the lungs of the mice 
or determine the virus titers in the stock. 
2.14 RNA extraction, Reverse Transcription and Real Time PCR 
        Extraction of RNA samples from cells and homogenized tissues was done 
using Trizol® (Invitrogen). 200 µl of chloroform (Sigma, USA) per 1 ml of 
Trizol® was added to the samples and centrifuged at 13,200 rpm for 15 min at 
4oC. The aqueous phase was aliquoted; 500 µl of isopropanol (Sigma, USA) was 
added to it and centrifuged at 13,200 rpm for 10 min at 4oC to precipitate the 
RNA. The RNA pellet was washed with 750 µl of cold 75% ethanol (Sigma, 
USA) and centrifuged at 13,200 rpm for 5 min at 4oC. The RNA pellet was then 
resuspended in 20 µl of DEPC-treated water (Invitrogen, USA) and the 
concentration of RNA samples were measured by BioTek® Microplate Reader. 
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1 µg of the isolated RNA was added to oligo-dT primers (Promega, USA) 
and Improm-II Reverse Transcription kit (Promega, USA) according to the 
manufacturer’s instruction to synthesize the cDNA. cDNA was prepared using 
ImProm-IITM Reverse Transcription System (Promega, USA). Briefly, 1 μg of 
RNA diluted in 4 μl DEPC-treated H2O was first added 1 μl of Oligo(dT)15 
Primer, and the mixture was incubated at 70°C for 5 min and 4°C for 5 min using 
the Thermo Cycler (Bio-Rad Laboratories, USA). The reaction mixture was 
subsequently added to 4.2 μl of nuclease free water, 4 μl of ImProm-II 5X 
reaction buffer, 4.8 μl of magnesium choloride, 1 μl of dNTP mix, and 1 μl of 
ImProm-II Reverse Transcriptase to form a total of 20 μl solution. The solution 
was then subjected to cycling conditions of 25°C for 5 min, 42°C for 60 min, 
70°C for 15 min, and 4°C at infinity using T100TM Therrmal Cycler (Bio-Rad 
Laboratories, USA). The cDNA synthesized as the final product was stored at -
20°C for subsequent use. 
qRT-PCR was run on the cDNA samples using the CFX Connect RT-PCR 
machine (Bio-rad) at 95oC for 3 min followed by 95oC for 10 sec and 60oC for 30 
sec for 40 cycles. SYBR® Green master mix (Bio-rad), 1 μl of cDNA and 1 μl of 
primers mixture for relevant genes (Table 2.14) were used for qRT-PCR 
according to the manufacturer’s protocol. In order to normalize of the amount of 
cDNA between samples, Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
was used as an endogenous control. Relative gene expression levels were 
calculated using 2-∆∆Ct method (Livak and Schmittgen 2001) . Specificity of 
amplification reactions was confirmed by melting curve analysis to check the 
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specificity of primer pairs. 
 
Table 2. 14 Specific primer pairs for RT-PCR 
GAPDH Forward GAGAACTTTGGCATTGTGG 
Reverse ATGCAGGGATGATGT TCTG 
IFN-α Forward AGGCTCAAGCCATCCCTGT 
Reverse CAGGGGCTGTGTTTCTTCTC 
IFN-β Forward CCCTATGGAGATGACGGAGA 
Reverse CTGTCTGCTGGTGGAGTTCA 
IL-6 Forward GATGCTACCAAACTGGATATAATC 
Reverse GGTCCTTAGCCACTCCTTCTGTG 
TNF-α Forward TCCCAGGTTCTCTTCAAGGGA 
Reverse GGTGAGGAGCACGTAGTCGG 
RANTes Forward ATATGGCTCGGACACCA 
Reverse ACACACTTGGCGGTTCCT 
ISG15 Forward AACTGCAGCGAGCCTCTGA 
Reverse CACCTTCTTCTTAAGCGTGTCTACAG 
2’-5’ OAS Forward CTTTGATGTCCTGGGTCATGT 
Reverse GCTCCGTGAAGCAGGTAGAG 
HA Forward AGTGCCCAAAATACGTCAGG 
Reverse TCCCGTTAATGGCATTTTGT 






IL12p40  Forward CTTGCAGATGAAGCCTTTGAA GA 
Reverse GGAACGCACCTTTCTGGTTACA 
Arg1  Forward CTCCAAGCCAAAGTCCTTAGAG 
Reverse AGGAGCTGTCATTAGGGACATC 
Chi3l3 Forward AGAAGGGAGTTTCAAACCTGGT 
Reverse GTCTTGCTCATGTGTGTAAGTGA 
Mgl1 Forward TGAGAAAGGCTTTAAGAACTGGG 
Reverse GACCACCTGTAGTGATGTGGG 
IL-10 Forward GCTCTTACTGACTGGCATGAG 
Reverse CGCAGCTCTAGGAGCATGTG 
HPRT Forward AAGGACCTCTCGAAGTGTTGGATA 
Reverse CATTTAAAAGGAACTGTTGACAACG 
 
2.15 Enzyme-linked immunosorbent assay (ELISA) 
Concentrations of TNF-α and IL-6 cytokines in the cell culture supernatants 
was determined by sandwich ELISA using 96-well MaxiSorpTM Immunoplates 
(Nunc, USA). The wells were pre-coated with 100 µl of 1 µg/ml TNF-α and IL-6 
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capture antibodies (BD Pharmingen, USA) diluted in PBS and the plates were 
incubated overnight at 4oC. The following day, the wells were washed once with 1 
x PBS containing 0.05% Tween-20 (Sigma-Aldrich) after which blocking of the 
wells was done using blocking solution (5% BSA (PAA, Austria) in PBS) at 37oC 
for 1 h. After 1 h, the wells were again washed once with PBS. The samples as 
well as standards for the respective cytokines (which were serially diluted in 
blocking solution) were added to the wells and incubated for 3 h at 37oC. The 
plates were again washed three times and 100 µl/well of 1 µg/ml biotinylated 
detection antibodies (BD Pharmigen, USA) diluted in blocking solution were 
added after which the plates were incubated at room temperature for 1 h. 
Following 3 more washes, 100µl/well of 1 µg/ml streptavidin-HRP (Biolegend, 
USA) was added and incubated at room temperature for 1 h. Next the plates were 
washed 6 times. O-phenylenediamine dihydrochloride (OPD) (Sigma, USA) was 
dissolved in distilled H2O and added as substrate to the plate and incubated at 
room temperature for 15 min and the reactions were stopped by addition of 4.5N 
H2SO4 (Merck, Germany). The optical density of each well was read at 
absorbance 490 nm using the BioTek® Synergy H1 Hybrid Multi-Mode 
Microplate Reader to determine the concentration of the cytokines.  
Specific MCP-1 ELISA kit (eBioscience), IFN-α and IFN-β ELISA kit (PBL 
Interferon Source) were used for the measurement of MCP-1, IFN-α and IFN-β 
concentrations according to the manufacturer’s protocol. The concentration was 
determined by reading the plates at 450 nm absorbance using the BioTek® 
Microplate Reader. A standard curve using the absorbance values was plotted for 
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each cytokine measured to obtain the concentration of the cytokines in the 
samples. 
2.16 Western blot 
Cell lysates prepared as previously described (Zhang, Li et al. 2009) were 
resolved in 10% or 12% Tris/Glycine resolving gel (10% or 12% acrylamide, 1.5 
M Tris (pH 8.8), 10% SDS, 10% APS, Tetramethylethylenediamine). The proteins 
were probed with anti-phospho-ERK, anti-ERK, anti-phospho-p38, anti-p38, anti-
phospho-JNK and anti- JNK antibodies (Cell Signaling Technology) for MAPKs 
activation; anti-phospho-IRF3 (Ser396), anti-IRF3 (Cell Signaling Technology) 
for IRF3 phosphorylation; and anti-phospho-TBK1 for TBK1 phosphorylation; 
anti-TBK1, anti-IKKε, actin (Cell Signaling Technology), anti-MKP-2 (Santa 
Cruz), anti-flag (Sigma-Aldrich) and anti-HA (Zymed) for their expression, 
respectively. BMDMs were infected with PR8 with a MOI of 1 or stimulated with 
5’-ppp dsRNA (0.5 μg/mL) for 1 h, 3 h and 6 h. The proteins were first lysed with 
NP lysis buffer containing protease inhibitors, Complete mini (Roche, USA) and 
PMSF (Sigma, USA), and next resolved in 10% SDS-polyacrylamide (Bio-Rad, 
USA) gels and transferred onto PVDF membrane (Bio-Rad, USA) via wet 
transfer. Using 5% milk in TBST, the blot was blocked at room temperature for 1 
h, followed by an overnight incubation at 4oC with primary antibodies (Cell 
Signaling, USA) diluted at 1:1000. Next, HRP-conjugated secondary antibodies 
(GE Healthcare, USA) diluted at 1:4000 was added and incubated at room 
temperature for 1 h. The signal was detected with ECL reagent (Pierce Chemical 
Co.). Total activation level of each MAPK, IRF3 and TBK1 was normalized to the 
total expression of each MAPK, IRF3 and TBK1 in the samples respectively. The 
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intensity of the indicated bands was measured using ImageJ software.  
2.17 Immunoprecipitation 
HEK293T cells were lysed in 250 μl NP40 lysis buffer containing freshly 
added protease and phosphatase inhibitors (Roche). Lysates were incubated with 
anti‐FLAG antibody conjugated to agarose beads (Sigma) or anti-HA antibody 
conjugated to agarose beads at 4°C overnight. The beads were washed with lysis 
buffer to remove unspecific binding and SDS loading dye was added to the beads. 
The bound protein complexes were eluted by heating the beads at 95°C and the 
proteins were analyzed by western blotting. Primary antibodies, polyclonal anti‐
FLAG (Sigma), anti‐HA (Zymed), anti‐phospho‐ERK1/2 (Cell Signaling 
Technology), secondary antibody; Donkey anti-rabbit HRP- conjugated 
(Amersham biosciences) were used. 
2.18 Cell Surface Markers and Flow Cytometry Analysis 
Lung tissues single cells suspensions were isolated from mice as described in 
section 2.5 and blocked with purified rat anti-mouse Fc Block-CD16/CD32 (BD 
Biosicence, USA) at 4oC for 15 min to prevent unspecific binding of staining 
antibodies in the steps that followed. Fluorochrome labeled antibodies Percp-Gr-1 
(1:100), APC-CD11b (1:100), APC-CD11c (1:100), FITC-MHCII (1:100) and 
PE-CD45.2 (1:300) (eBiosciences, USA) were diluted in staining buffer (2% BSA 
in PBS) and added to the cell suspensions to stain the cells’ surface markers. The 
cells were left at 4oC for 30 min after which the cells were washed with PBS and 
fixed in 2% paraformaldehyde (Sigma, USA). Cells were sorted and analysed 
using the BD FACSCalibur Flow Cytometer (BD Bioscience, USA) and analysis 
data was acquired using the BD CellQuest Pro software. Cell populations were 
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sorted using FlowJo software version 7.6.3 (Tree Star Inc., USA). Selection of 
live cells was done using forward and side scatter, where leukocytes stained 
CD45.2 positive were gated as a subset of live cells. The different immune cell 
types were identified based on the cell markers present on the cells: neutrophils 
(CD11b+/Gr-1+), macrophages (CD11c+/MHCII Intermediate) and DCs 
(CD11c+/MHCII High). The percentages of these different cell populations were 
calculated against the initial total cell count in each sample to derive the absolute 
number of each specific cell types. 
The differentiated BMDMs and BMDCs were stained with APC-CD11b 
(1:100) or APC-CD11c (1:100) (eBioscience) at 4oC for 30 min. Analysis of the 
cell sorting was done on BD FACSCalibur Flow Cytometer (BD Bioscience, 
USA) and analysis data was acquired using the BD CellQuest Pro software. 
FlowJo software version 7.6.3 (Tree Star Inc., USA) was used to sort out the cell 
populations. 
2.19 Dual Luciferase Assay 
293T cells seeded on 24-well plates were transfected with 400 ng/mL IFN-β 
promoter, MKP-2 expression plasmid or empty plasmid together with a total of 
600 ng of various expression plasmids including MAVS, TBK1, IKKε and IRF3. 
As an internal control, 10 ng pRL-TK Renilla was transfected simultaneously. 18 
h after transfection, the cells were washed with PBS and lysed in passive lysis 
buffer (Promega, USA) for 1 h at room temperature. The luciferase activity was 
then measured in whole cells lysates using the Dual Luciferase Assay System 
(Promega) according to manufacturer’s instruction.  
In AP-1 promotor activity assays, 2 × 105 RAW264.7 cells were 
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cotransfected with 50 ng AP-1 reporter construct, 50 ng pcDNA3.1-MKP-2 
together with 10 ng of the pRL-null plasmid by using Lipofectamine LTX reagent 
(Invitrogen). Equal amounts of pcDNA3.1 empty vector were transfected as 
control. Reporter activity was determined using the Promega® Dual Luciferase 
Assay System (Promega). Firefly luciferase values were normalized for 
transfection efficiency by means of the Renilla luciferase activity that is 
constitutively expressed by pRL-null to account for the differences in transfection 
efficiencies between samples. 
2.20 Immunofluorescence and Confocal Microscopy 
BMDMs were grown on glass coverslips and infected with PR8 virus at MOI 
of 2 for 6 h, along with controls without infection. Cells were fixed using 3.7% 
formaldehyde (Sigma-Aldrich) for 15 min at 37°C. Next the fixed cells were 
washed twice with PBS, twice with 4 mM NH4Cl (Sigma-Aldrich) in PBS, twice 
with PBS and permeabilised with 0.2% Triton X‐100 (BioRad) in PBS for 15 min 
at room temperature. Followed by washing, the cells were blocked with 2% 
bovine serum albumin and 7% FBS in PBS for 60 min at room temperature. Cells 
were then incubated with rabbit anti‐IRF3 antibody (Santa Cruz) in blocking 
solution overnight. The following day, samples were washed three times with 
0.1% Triton X‐100‐containing PBS before incubation with Alexa Fluor 633‐
conjugated donkey anti‐rabbit IgG (Life Technologies) for 60 min. The samples 
were next washed three times with 0.1% Triton X‐100‐containing PBS and 
incubated with DAPI  (Life Technologies) for 5 min, washed twice again and 
mounted using Fluorsave (Merck Millipore). Zeiss LSM510 META microscope 
was used to capture confocal fluorescence images. Average nuclear fluorescent 
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intensity (ANFI) of the cells were quantified by ImageJ. 
2.21 Generation of MKP-2 overexpressing RAW264.7 
pcDNA3.1-MKP-2 and pcDNA3.1 empty vector were transfected into the 
RAW264.7 cells by lipofectamine LTX (Invitrogen) (section 2.11). The cells were 
transferred to 10-mm dishes on the second day and 500 μg/mL G418 (Clontech) 
were added to the plate to select the positive cells for 14 days. The media were 
changed every 2 days. After selection, the mRNA and protein expression of MKP-
2 were measured to confirm the overexpression of MKP-2 in RAW264.7. The 
positive cells were maintained in complete medium in the presence of 100 ng/mL 
G418. 
2.22 Co-culture of Adipocytes and Macrophages 
        Co-culture of adipocytes and macrophages was performed in the contact 
system. Differentiated 3T3-L1 adipocytes were cultured in a 6-well plate and 105 
RAW264.7 cells were plated onto 3T3-L1 adipocytes. The cells were co-cultured 
for 24 h followed by pamitate stimulation for another 24 h, after which the 
supernatants were harvested. As a control, adipocytes and macrophages, the 
numbers of which were equal to those in the contact system, were cultured 
separately. 
2.23 Statistical Analysis 
        Two-tailed Students t test (Excel, Microsoft Office) was used for comparison 
between two groups. Data is expressed as Mean + Standard Error of Mean (SEM). 




Chapter 3 MAP Kinase Phosphatase 2 negatively regulates type-I 
IFNs response to influenza infection 
3.1 MKP-2 KO mice are resistant to influenza virus infection compared to 
WT mice 
3.1.1 Reduced influenza viral loads in the lungs from MKP-2 KO mice upon 
influenza virus infection 
        To examine the function of MKP-2 in response to influenza infection in vivo, 
we infected WT and MKP-2 KO mice with PR8 viruses (500 pfu) by intranasal 
virus inoculation. The mice were sacrificed on day 2, 3 and 5 P.I.. Viral titers in 
the lungs were determined by plaque assay. 
        As shown in Fig. 3.1, viral titers in the lungs from MKP-2 KO mice 
exhibited 1.5-3 times reduction on day 2, 3 and 5 P.I. compared with these in the 
lungs from WT mice, indicating that deficiency of MKP-2 resulted in reduced 
viral loads in the lung. 
 
 
Figure 3. 1 Viral titers in the lungs of WT and MKP-2 KO mice upon PR8 infection 
WT and MKP-2 KO mice (4-5 mice / group) were infected with PR8 through the intranasal route 
with pfu: 500. Viral titers in the lungs on day 2, 3, and 5 P.I. were determined by plaque assay. The 
data shown are a representative of 3 independent experiments with similar results. Data are 
presented as mean + SEM. *p<0.05. 
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3.1.2 Reduced disease severity in MKP-2 KO mice upon influenza virus infection 
       To evaluate the impact of the decreased viral loads caused by the deficiency 
of MKP-2 on disease severity upon influenza infection, we measured the body 
weight of the infected mice daily and the percentage of body weight loss of the 
mice was determined until day 11 upon PR8 infection (pfu: 50). 
 
 
Figure 3. 2 Percentage of body weight loss in WT and MKP-2 KO mice upon PR8 infection 
WT and MKP-2 KO mice (4-5 mice / group) were infected with PR8 through the intranasal route 
with pfu: 50. Changes in body weight of WT and MKP-2 KO mice P.I. were monitored daily. The 
data shown are a representative of 3 independent experiments with similar results. Data are 
presented as mean + SEM. *p<0.05, **p<0.01. 
 
        As shown in Fig. 3.2, both WT and MKP-2 KO mice started to lose weight 
on day 6 P.I. and reached the maximum of weight loss on day 9 P.I. followed by 
the recovery. Interestingly, we observed significantly less percentages of weight 
loss in MKP-2 KO mice compared with those in WT mice. This data 
demonstrated that MKP-2 KO mice are more resistant to influenza virus infection 
than WT mice.  
Due to the recovery of the mice at this stage, we didn’t detect virus in the 
lung tissues from both WT and MKP-2 KO mice on day 11 P.I. by plaque assay. 
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As plaque assay is limited in sensitivity, we examined the expression of Ha and 
Na, the two viral surface antigens primarily involved in the induction of specific 
humoral immunity to influenza virus by quantitative real-time PCR (qRT-PCR), 
which is a surrogate marker to evaluate the level of virus in host tissues 
(Johansson, Bucher et al. 1989). We found that the expression of Ha and Na genes 
was dramatically attenuated in the lungs from MKP-2 KO mice than WT mice 
(Fig. 3.3). Collectively, MKP-2 KO mice developed reduced disease severity 
upon PR8 infection associated with decreased viral loads. 
 
 
Figure 3. 3 Relative Ha and Na expression in the lungs of WT and MKP-2 KO mice on day 
11 P.I. 
WT and MKP-2 KO mice (4-5 mice / group) were infected with PR8 through the intranasal route 
with pfu: 50. Relative viral genes Ha and Na expression was examined by qRT-PCR. The data 
shown are a representative of 3 independent experiments with similar results. Data are presented 
as mean + SEM. *p<0.05. 
 
3.1.3 Increased type-I IFNs, IL-6 and TNF-α expression in lungs of MKP-2 KO 
mice upon influenza virus infection 
        The production of various cytokines and chemokines by the host plays 
critical roles in restricting viral replication in the lungs (Julkunen, Sareneva et al. 
2001). Particularly, type-I IFNs including IFN-α and IFN-β are essential 
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components of host anti-viral defense (Sadler and Williams 2008, Gonzalez-
Navajas, Lee et al. 2012). Hence, we collected the BALs from both WT and 
MKP-2 KO mice on day 2, 3 P.I. to determine the concentrations of type-I IFNs, 
IL-6 and TNF-α by ELISA. 
 
 
Figure 3. 4 Type-I IFNs, IL-6 and TNF-α productions in BALs and expression in the lungs of 
WT and MKP-2 KO mice on day 2 upon PR8 infection 
WT and MKP-2 KO mice (4-5 mice / group) were infected with PR8 through the intranasal route 
with pfu: 500 and sacrificed on day 2 P.I. (A) Type-I IFNs, IL-6 and TNF-α productions in BALs 
were examined by ELISA. (B) Type-I Ifns, Il-6 and Tnf-α genes expression was examined by qRT-
PCR. The data shown are a representative of 3 independent experiments with similar results. Data 




Figure 3. 5 Type-I IFNs, IL-6 and TNF-α productions in BALs and expression in the lungs of 
WT and MKP-2 KO mice on day 3 upon PR8 infection 
WT and MKP-2 KO mice (4-5 mice / group) were infected with PR8 through the intranasal route 
with pfu: 500 and sacrificed on day 3 P.I. (A) Type-I IFNs, IL-6 and TNF-α productions in BALs 
were examined by ELISA. (B) Type-I Ifns, Il-6 and Tnf-α genes expression was examined by qRT-
PCR. The data shown are a representative of 3 independent experiments with similar results. Data 
are presented as mean + SEM. *p<0.05. 
 
Interestingly, it was found that the concentrations of both IFN-and IFN- 
were significantly elevated in the BALs from MKP-2 KO mice on day 2 and 3 P.I. 
compared with these in WT mice (Fig. 3.4A and Fig.3.5A). The concentrations 
of IL-6 and TNF-α in BALs were also modestly elevated in MKP-2 KO mice on 
day 2 and 3 P.I. compared with WT mice (Fig. 3.4A and Fig.3.5A), although the 
differences were not statistically significant.  
The lungs of the WT and MKP-2 KO mice on day 2 and day 3 P.I. were 
homogenized in Trizol Reagent to extract RNA to examine the expression of 
type-I Ifns, Il-6 and Tnf-α by qRT-PCR. Consistent with the ELISA data, mRNA 
expression of these genes was also upregulated in the lungs from MKP-2 KO 
mice on day 2 and day 3 P.I. compared with WT mice (Fig. 3.4B and Fig. 3.5B), 
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although the differences were not statistically significant. A possible explanation 
for the difference in protein and mRNA expression is that the transcription of a 
certain gene from DNA to mRNA happens earlier than the translation of proteins 
from mRNA. These data demonstrates that the deficiency of MKP-2 results in 
enhanced type-I Ifns, Il-6 and Tnf-α expression upon influenza virus infection. 
This provides evidence that increased type-I IFNs productions upon influenza 
virus infection could enhance the influenza virus clearance ability in MKP-2 KO 
mice. 
3.1.4 Comparable innate immune cells infiltration in the lungs from WT and 
MKP-2 KO mice upon influenza virus infection 
Influenza virus infection triggers a rapid infiltration of leukocytes, which 
contributes to inflammation, activation of immune responses, as well as lung 
injury (Maines, Szretter et al. 2008, Perrone, Plowden et al. 2008). To elucidate 
the possible explanation for increased type-I IFNs production in MKP-2 KO mice 
P.I., we analyzed the cellular infiltration in lungs from WT and MKP-2 KO mice 
on day 3 P.I. The lungs were digested by collagenase to make single cell 
suspensions. The cells were stained with antibodies against different surface 





Figure 3. 6 Gating strategy of innate immune cells infiltration in lungs of mice upon PR8 
infection 
Single cells suspensions of digested lung tissues were stained with CD45.2, Gr-1 and CD11b for 
neutrophils (A), CD45.2, MHCII and CD11c for macrophages (B) and DCs (C) analysis. The 
populations of the cells stained were presented as scatter blot. 
 
Fig. 3.6 shows the gating of neutrophils, macrophages and DCs in during 
analysis after running the samples in flow cytometry. The neutrophil population 
was gated as Gr-1 positive and CD11b positive. The macrophages population was 
gated as CD11chigh and MHCIIintermediate and the DCs population was identified as 
CD11chigh and MHCIIhigh. 
        Fig. 3.7 and Fig. 3.8 present the percentages and total numbers of different 
innate immune cells infiltrated in the lungs of WT and MKP-2 KO mice on day 2, 
day 3 and day 5 P.I.. As shown in Fig. 3.7, upon infection, there is dramastically 
increasing percentage and total number of neutrophils infiltrated to the lungs. 
However, the percentage and total number of neutrophils are comparable. 
Meanwhile, the percentages and total numbers of macrophages and DCs were also 
comparable between MKP-2 KO and WT mice (Fig. 3.8). These data indicate that 
the increased production of type-I IFNs, IL-6 and TNF-α in the lungs of MKP-2 
KO mice is not due to increased innate immune cell infiltration, indicating that 
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deficiency of MKP-2 resulted in enhanced expression of type-I IFNs, IL-6 and 
TNF-α by these cells upon influenza virus infection. 
 
 
Figure 3. 7 Leukocyte and neutrophil population analysis in WT and MKP-2 KO mice on 
day 2, 3 and 5 upon PR8 infection 
WT and MKP-2 KO mice (4-5 mice / group) were infected with PR8 through the intranasal route 
with pfu: 500 and sacrificed on day 2, 3 and 5 P.I. (A) the percentage of neutrophils was analyzed 
by flow cytometry according to the gating strategy described in Fig. 3.6. (B) Total numbers of 
neutrophils were calculated based on the percentages of gatings described in Fig. 3.6. The 
populations of the cells stained were presented as scatter blot. The data shown are a representative 




Figure 3. 8 Macrophages and DCs population analysis in WT and MKP-2 KO mice on day 2, 
3 and 5 upon PR8 infection 
WT and MKP-2 KO mice (4-5 mice / group) were infected with PR8 through the intranasal route 
with pfu: 500 and sacrificed on day 2, 3 and 5 P.I. (A) the percentages of macrophages and DCs 
were analyzed by flow cytometry according to the gating strategy described in Fig. 3.6. (B) Total 
numbers of macrophages and DCs were calculated based on the percentages of gatings described 
in Fig. 3.6. The populations of the cells stained were presented as scatter blot. The data shown are 
a representative of 3 independent experiments with similar results. Data are presented as mean + 
SEM.  
 
3.2 Increased type-I IFNs, IL-6 and TNF-α expression and IRF3 activation in 
MKP-2 KO cells upon influenza virus infection 
3.2.1 Increased type-I IFNs, IL-6 and TNF-α expression in MKP-2 KO BMDMs 
and BMDCs upon PR8 infection 
Type-I IFNs are crucial for innate immune response against viral infection 
(Levy, Marie et al. 2011). Lung macrophages and DCs, two of the major cells 
infiltrated into the lung upon influenza infection, are able to produce vigorous 
amounts of pro-inflammatory cytokines and type-I IFNs (Hui, Lee et al. 2009, 
Michaelis, Doerr et al. 2009, Kallfass, Lienenklaus et al. 2013). Therefore, we 
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examined the regulation of type I IFN expression by MKP-2 in both macrophages 
and DCs in vitro upon influenza virus infection. 
Bone marrow cells from WT and MKP-2 KO mice were cultured in the 
presence of M-CSF or GM-CSF, respectively to generate macrophages and DCs. 
After differentiation, the cells were stained with CD11b and F4/80 to check the 
purity of macrophages or CD11c for DCs. From the data presented in Fig. 3.9, we 
found that the percentages of CD11b and F4/80 double positive BMDMs 
differentiated from WT and MKP-2 KO mice were both above 95% on day 7 post 
differentiation. Similarly, the percentages of CD11c positive BMDCs 
differentiated from WT and MKP-2 KO mice were comparably around 94% on 
day 9 post differentiation. This data indicate the success of BMDMs and BMDCs 





Figure 3. 9 BMDMs and BMDCs differentiation 
(A) The bone marrow cells were differentiated in complete medium supplemented with 20 ng/mL 
of M-CSF for 7 days. The differentiated BMDMs were stained with CD11b, F4/80 and analyzed 
by flow cytometry. (B) The bone marrow cells were differentiated in complete medium 
supplemented with 20 ng/mL of GM-CSF for 9 days. The differentiated BMDCs were stained with 
CD11c and analyzed by flow cytometry.  
 
To delineate the function of MKP-2 in the regulation of type-I Ifns 
expression in response to influenza virus infection, WT and MKP-2 KO BMDMs 
were infected with PR8 virus (MOI: 1) for various time points. Total RNAs were 
extracted at 6 h after PR8 infection for qRT-PCR to analyze genes expression. 





Figure 3. 10 Type-I IFNs, IL-6 and TNF-α productions and expression in WT and MKP-2 
KO BMDMs upon PR8 infection 
WT and MKP-2 KO BMDMs were infected with PR8 virus (MOI: 1) for indicated time points. (A) 
Relative mRNA expression of indicated cytokines was determined by RT-PCR 6 h P.I. (B) The 
productions of IFN-α and IFN-β in culture supernatants were measured by ELISA 24 h P.I. The 
productions of IL-6 and TNF-α in culture supernatants were measured by ELISA 48 h P.I. The 
data shown are a representative of 3 independent experiments with similar results. Data are 
presented as mean + SEM. *p<0.05, **p<0.01, ***p<0.001. 
 
As can be seen in Fig. 3.10, upon PR8 infection, both mRNA and protein 
expression of pro-inflammatory cytokines IL-6 and TNF-α were greatly induced 
in BMDMs. Interestingly, MKP-2 KO BMDMs expressed significantly higher 
amount of these cytokines at both mRNA and protein levels. This result is in 
agreement with a previous study, which showed that IL-6 and TNF-α expression 
was elevated in MKP-2 KO BMDMs in response to LPS stimulation (Al-Mutairi, 
Cadalbert et al. 2010). Importantly, IFN-α and IFN-β expression was observed to 
be significantly enhanced in MKP-2 KO BMDMs post PR8 infection in both 




Figure 3. 11 Type-I IFNs, IL-6 and TNF-α productions and expression in WT and MKP-2 
KO BMDCs upon PR8 infection 
WT and MKP-2 KO BMDCs were infected with PR8 virus (MOI: 1) for indicated time points. (A) 
Relative mRNA expression of indicated cytokines was determined by RT-PCR 6 h P.I. (B) The 
productions of IFN-α, IFN-β, IL-6 and TNF-α in culture supernatants were measured by ELISA 
24 h P.I. The data shown are a representative of 3 independent experiments with similar results. 
Data are presented as mean + SEM. *p<0.05, **p<0.01, ***p<0.001. 
 
In MKP-2 KO BMDCs, increased mRNA expression of Ifn-α, Ifn-β and Tnf-
α but not Il-6 was detected compared with WT BMDCs at 6 h P.I. (Fig. 3.11A). 
However, the concentrations of IFN-α, IFN-β, IL-6 and TNF-α were all observed 
to be significantly elevated in the culture supernatants of MKP-2 KO BMDCs 
compared with these from WT BMDCs (Fig. 3.11B). 
Taken together, these results suggest that MKP-2 acts as a negative regulator 
of type-I Ifns expression in both macrophages and DCs in response to influenza 
infection, which has not been previously reported. The results support the in vivo 
data that MKP-2 KO mice expressed higher type-I Ifns after influenza infection. 
3.2.2 Increased IRF3 activation in MKP-2 KO BMDMs upon PR8 infection 
IRF3 is the master regulator of type-I Ifns expression in response to virus 
infection (Hiscott 2007). Phosphorylation of Ser396 in IRF3 is a critical step in 
IRF3 activation (Servant, Grandvaux et al. 2003, McCoy, Carpenter et al. 2008). 
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Once phopshorylated, IRF3 will translocate from the cytoplasm to the nucleus to 
regulate type-I Ifns expression (Ishikawa and Barber 2011). Thus, we compared 
the phosphorylation of Ser396 in IRF3 from WT and MKP-2 KO BMDMs in 
response to PR8 infection.  
As shown in Fig. 3.12A, IRF3 phosphorylayion was greatly induced 6 h after 
PR8 infection (Fig. 3.12A). Importantly, IRF3 phosphorylation was dramatically 
enhanced at 6 h after PR8 infection in MKP-2 KO BMDMs compared with that in 
WT BMDMs (Fig. 3.12A). The relative IRF3 phosphorylation level was 
normalized to the total protein expression IRF3 (Fig. 3.12B) and was found that 
there was a 3-fold increase of IRF3 phosphorylation at 6h upon PR8 infection in 
KO cells. These data indicate that MKP-2 negatively regulated IRF3 
phosphorylation in response to PR8 infection. 
 
Figure 3. 12 IRF3 signaling activated in WT and MKP-2 KO BMDMs upon PR8 infection 
WT and KO BMDMs were infected with PR8 virus (MOI: 1) for indicated time points. (A) The 
protein samples were harvested for p-IRF3, IRF3, p-TBK1, TBK1, IKKε and actin western blot 
analysis. (B) Quantification of band intensity p-IRF3, p-TBK1 and IKKε levels was normalized to 
total IRF3 levels, total TBK1 and actin levels respectively. The data shown are a representative of 
3 independent experiments with similar results. 
 70 
IRF3 is phosphorylated by the upstream kinases TBK1 and IKKε that lead to 
its nuclear translocation and subsequent regulation of expression of type-I Ifns in 
response to virus infection (Tripathi, White et al. 2013). Hence, we determined the 
TBK1 and IKKε activation and expression by western blot. As can be seen in Fig. 
3.12, TBK1 activation was comparable between WT and MKP-2 KO BMDMs 
post PR8 infection when normalized to total TBK1 protein (Fig. 3.12). 
Phosphorylated IKKε was not detectable in both WT and KO cells upon PR8 
infection. Total expression of IKKε was found to be comparable between WT and 
MKP-2 KO BMDMs (Fig. 3.12). These data manifests that the increased IRF3 
phosphorylation in MKP-2 KO BMDMs was not due to elevated activation of 
TBK1 or IKKε.  
Next, we examined whether elevated phosphorylation of IRF3 in MKP-2 KO 
BMDMs upon PR8 infection leads to enhanced translocation by IRF3 
immunostaining. We observed that without infection, IRF3 was predominantly 
located in the cytoplasm in both WT and MKP-2 KO cells (Fig. 3.13). Upon 
influenza virus infection, IRF3 nuclear localization is greatly enhanced in both 
WT and MKP-2 KO cells indicated by the measurement of average nuclear 
fluorescence intensity (ANFI) (Fig. 3.13). Importantly, significantly increased 
IRF3 nuclear localization in MKP-2 KO cells compared with WT cells was 
detected after infection. In line with increased IRF3 nuclear localization, relative 
expression of several Isgs including Isg-15 and Rantes was upregulated in MKP-2 
KO BMDMs and BMDCs compared with WT cells post PR8 infection (Fig. 3.14).  
Collectively, the data shown above demonstrate that MKP-2 negatively 
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regulates IRF3 phosphorylation and nuclear translocation in BMDMs post 
influenza virus infection, which resulted in increased expression of type I Ifns.  
 
 
Figure 3. 13 Endougenous IRF3 immunostaining in WT and MKP-2 KO BMDMs with or 
without PR8 infection 
WT and MKP-2 KO BMDMs were infected with or without PR8 virus at MOI of 2 for 6 h. 
Subcellular localization of IRF3 was determined by IRF3 immunostaining and confocal 
fluorescence images were captured. Average nuclear fluorescent intensity (ANFI) of 100 cells was 
quantified using Image J. The data shown are a representative of 3 independent experiments with 
similar results. Data are presented as mean + SEM. *p<0.05. 
 
 
Figure 3. 14 Isgs expression in WT and MKP-2 KO BMDMs upon PR8 infection 
(A) WT and KO BMDMs were infected with PR8 virus (MOI: 1) for 6 h. The gene expression of 
Isgs including Rantes and Isg-15 was determined by RT-PCR 6 h after infection by PR8 virus. (B) 
WT and KO BMDCs were infected with PR8 virus (MOI: 1) for 6 h. The gene expression of Isgs 
including Rantes and Isg-15 was determined by RT-PCR 6 h after infection by PR8 virus. The 
data shown are a representative of 3 independent experiments with similar results. Data are 
presented as mean + SEM. *p<0.05, **p<0.01. 
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3.2.3 Increased ERK activation in MKP-2 KO BMDMs upon influenza virus 
infection 
As a member of MKPs, MKP-2 has been controversially shown to negatively 
regulate p38/JNK or ERK activation in BMDMs after LPS stimulation (Al-
Mutairi, Cadalbert et al. 2010, Cornell, Rodenhouse et al. 2010). To understand 
the regulation of MAPK activation by MKP-2 upon virus infection, we examined 
MAPKs activation in WT and MKP-2 KO BMDMs upon PR8 infection. p38 and 
ERK activation were found to be upregulated upon PR8 infection whereas JNK 
activation was not detectable in macrophages (Fig. 3.15). Surprisingly, ERK 
activation was enhanced in MKP-2 KO BMDMs, whereas the activation of p38 
was comparable between WT and KO cells at various time points P.I. (Fig. 3.15).  
The results indicate that MKP-2 negatively regulates ERK activation in 





Figure 3. 15 MAPKs signaling activated in WT and MKP-2 KO BMDMs upon PR8 infection 
WT and KO BMDMs were infected with PR8 virus (MOI: 1) for indicated time points. (A) The 
protein samples were harvested and probed for p-ERK, ERK, p-p38, p38 and actin western blot 
analysis. (B) Band intensities of p-ERK and p-p38 levels were quantified and normalized to total 
ERK and p38 levels respectively. The data shown are a representative of 3 independent 
experiments with similar results. 
 
3.3 Increased type-I Ifns, Il-6 and Tnf-α expression in MKP-2 KO BMDMs 
and BMDCs in response to PRRs activation 
3.3.1 Increased type-I Ifns, Il-6 and Tnf-α expression in MKP-2 KO cells in 
response to PRRs activation 
In response to influenza infection, various cell types in lung tissues sense 
virus infection through TLRs and RLR ligands such as TLR3, TLR7/8 (TLR8 
only in human DCs) and RIG-I ligands (Iwasaki and Pillai 2014). To characterize 
the regulatory role of MKP-2 on signaling and type-I Ifns expression mediated by 
PRRs activation, we firstly quantified the relative Mkp-2 expression in response to 
TLR3 agonist poly (I:C) and RIG-I agonist 5’-ppp dsRNA stimulation. As shown 
in Fig. 3.16A, 3 h after both poly (I:C) and 5’-ppp dsRNA stimulation, Mkp-2 
mRNA expression was significantly increased in WT BMDMs. We observed that 
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MKP-2 protein was expressed in WT BMDMs without stimulation (Fig. 3.16B). 
Poly (I:C) dramatically increased MKP-2 protein expression at 3 h after 
stimulation. Together, these data suggests that MKP-2 is involved in immune 
responses mediated by TLR3 and RIG-I activation in macrophages. 
 
 
Figure 3. 16 Mkp-2 expression in response to poly (I:C) and 5’-ppp dsRNA stimulation 
(A) WT BMDMs were stimulated with poly (I:C) (0.5 μg/mL) and 5’-ppp dsRNA (0.5 μg/mL) for 
3 h, Mkp-2 gene expression was examined by qRT-PCR. (B) WT and MKP-2 KO BMDMs were 
stimulated with poly (I:C) (0.5 μg/mL) and 5’-ppp dsRNA (0.5 μg/mL) for indicated time points, 
MKP-2 protein expression was examined in response to poly (I:C) (0.5 μg/mL) by western blot. 
The data shown are a representative of 3 independent experiments with similar results. Data are 
presented as mean + SEM. *p<0.05. 
 
To further understand the role of MKP-2 in the regulation of type-I Ifns and 
pro-inflammatory cytokines expression upon TLR3 and RIG-I activation, we 
transfected WT and MKP-2 KO BMDMs with 0.5 μg/mL poly (I:C) or 0.5 μg/mL 
5’-ppp dsRNA, respectively. The relative gene expressions and secretion of type-I 
IFNs, IL-6 and TNF-α was measured. From the data presented in Fig. 3.17, we 
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found a significant elevation on the expression of type-I Ifns, Il-6 but not Tnf-α, in 
MKP-2 KO BMDMs at 6 h after poly (I:C) and 5’-ppp dsRNA stimulation. The 
increase of transcriptional activation of Ifn-α, Ifn-β and Il-6 upon activation of 
TLR3 and RIG-I by poly (I:C) and 5′-ppp dsRNA resulted in significantly higher 
secretion of these cytokines from MKP-2 KO BMDMs compared to WT BMDMs 
(Fig. 3.17). In contrast to the mRNA expression, TNF-α protein secretion by 
MKP-2 KO BMDMs was markedly enhanced compared with WT BMDMs, upon 
5′-ppp dsRNA stimulation (Fig. 3.17).  
 
Figure 3. 17 Type-I Ifns, Il-6 and Tnf-α expression and production in WT and MKP-2 KO 
BMDMs in response to TLR3 and RIG-I activation 
WT and KO BMDMs were transfected with poly (I:C) (0.5 μg/mL) or 5’-ppp dsRNA (0.5 μg/mL). 
(A) The mRNA expression of Ifn-α, Ifn-β, Il-6 and Tnf-α was determined by qRT-PCR 6 h after 
stimulation. (B) The concentrations of IFN-α, IFN-β, IL-6 and TNF-α in culture supernatants were 
measured by ELISA 24 h after stimulation. The data shown are a representative of 3 independent 
experiments with similar results. Data are presented as mean + SEM. *p<0.05, **p<0.01, 
***p<0.001. 
 
Similarly, we stimulated BMDCs with R848, a TLR7 agonist to characterize 
the role of MKP-2 in the regulation of type-I Ifns and pro-inflammatory cytokines 
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expression in response to TLR activation. As shown in Fig. 3.18, MKP-2 KO 
BMDCs exhibited significantly higher amounts of IFN-β secretion compared with 
WT BMDCs upon R848 stimulation, whereas IFN-α production was not 
detectable. IL-6 and TNF-α production was comparable between WT and MKP-2 
KO BMDCs post R848 stimulation. 
Taken together, these data indicate that deficiency of MKP-2 leads to 
increased cytokine expression in macrophages and DCs upon PRRs activation.  
 
 
Figure 3. 18 Ifn-β, Il-6 and Tnf-α expression and production in WT and MKP-2 KO BMDCs 
in response to R848 stimulation 
WT and KO BMDC were stimulated with R848 (100 ng/mL). (A) The concentrations of IFN-β, 
IL-6 and TNF-α in culture supernatants were measured by ELISA 6 h and 24 h after stimulation. 
(B) The mRNA expression of Ifn-β, Il-6 and Tnf-α was determined by qRT-PCR 6 h after 
stimulation. The data shown are a representative of 3 independent experiments with similar results. 
Data are presented as mean+SEM. *p<0.05, **p<0.01. 
3.3.2 Increased IRF3 and ERK activation in MKP-2 KO BMDMs in response to 
RIG-I activation 
The signaling pathways activated in WT and MKP-2 KO BMDMs after 5’-
ppp dsRNA stimulation were further examined. As can be seen in Fig. 3.19, IRF3 
phosphorylation was induced 1 h after 5’-ppp dsRNA transfection and reached the 
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highest-level at 3 h after transfection in both WT and KO cells. Consistent with 
the data obtained from PR8 virus infected samples, we observed obvious higher 
of IRF3 phosphorylation at 3 and 6 h in MKP-2 KO BMDMs compared with 
these in WT BMDMs, whereas TBK1 activation, IKKε expression and p38 
activation were comparable between WT and KO BMDMs. Interestingly, ERK 
activation was again observed to be increased and prolonged in MKP-2 KO 
BMDMs compared with WT BMDMs after 5’-ppp dsRNA stimulation. The data 
demonstrates that deficiency of MKP-2 enhances the activation of IRF3 and ERK 
in response to RIG-I ligand stimulation in BMDMs.  
 
 
Figure 3. 19 IRF3 and MAPKs signaling activated in WT and MKP-2 KO BMDMs upon 5’-
ppp dsRNA stimulation 
WT and KO BMDMs were stimulated with 5’-ppp dsRNA (0.5 μg/mL) for the indicated time 
points. (A) The protein samples were harvested for p-IRF3, IRF3, p-TBK1, TBK1, IKK, actin, p-
ERK, ERK, p-p38 and p38 western blot analysis. (B) Band intensities of p-IRF3, p-TBK1, p-ERK, 
p-p38 and IKKε levels were quantified and normalized to total IRF3, total TBK1, total ERK, total 
p38 and actin levels respectively. The data shown are a representative of 3 independent 
experiments with similar results. 
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3.4 MKP-2 inhibits upstream kinase-mediated IRF3 activation and IFN-β 
expression 
Multiple components, including MAVS and TBK1 have been reported to 
participate in virus-triggered Ifn-β expression. To examine how MKP-2 regulates 
the activation of IRF3 pathway leading Ifn-β expression, we transfected plasmids 
encoding these molecules and an IFN-β promoter luciferase construct together 
with or without MKP-2 full-length cDNA. It was found that overexpression of 
MKP-2 markedly inhibited IFN-β promoter activity mediated by over-expression 
of MAVS or TBK1 (Fig. 3.20), suggesting that MKP-2 functions as a negative 
regulator of MAVS and TBK1 mediated Ifn-β expression. 
 
 
Figure 3. 20 MKP-2 negatively regulates MAVS and TBK1 mediated IFN-β promoter 
activity 
The HEK293T cells were transfected with control or MKP-2 expressing plasmids and the 
indicated plasmids. IFN-β promoter activity was performed 24 h after transfection by dual 
luciferase assay. The data shown are a representative of 3 independent experiments with similar 
results. Data are presented as mean + SEM. *p<0.05, **p<0.01. 
 
To further understand the regulation of IRF3 activation by MKP-2, we 
transfected HEK293T cells with IRF3, IKKε together with MKP-2 expression 
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construct or empty vector. 24 h after transfection, cells were harvested for p-IRF3 
western blot analysis. As shown in Fig. 3.21, over-expression of IKKε 
dramatically induced IRF3 activation in HEK293T cells, which is in agreement 
with previous reports (Sharma, tenOever et al. 2003). Over-expression of MKP-2 
greatly inhibited IKKε-mediated IRF3 activation in HEK293T cells. Interestingly, 
it was also observed that over-expression of IKKε induced ERK activation in 




Figure 3. 21 MKP-2 negatively regulates IKKε mediated IRF3 activation in 293T cells 
HEK293T cells were transfected with HA-IRF3 and IKKε with or without Flag-tagged MKP-2. 
IRF3 and ERK activation in the whole cells lysates were analyzed by western blot analysis. The 
data shown are a representative of 3 independent experiments with similar results. 
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3.5 ERK inhibition decreased IRF3 activation and the expression of type-I 
Ifns and pro-inflammatory cytokines  
3.5.1 ERK interacts with MKP-2 and IRF3 in vitro 
To further understand the regulation of IRF3 by MKP-2, we examined if 
MKP-2 could interact with IRF3 using co-immunoprecipitation assay by 
transfecting Flag-tagged MKP-2 cDNA together with HA-tagged IRF3 into 293T 
cells. Lysates were subjected to immunoprecipitation using anti-Flag M2 beads or 
HA beads and analysed by western blot. IRF3 was co-immunoprecipitated with 
MKP-2 (Fig. 3.22A) while MKP-2 was also co-immunoprecipited with IRF3 (Fig. 
3.22B). Surprisingly, endogenous ERK was also co-immunoprecipitated with 
both MKP-2 and IRF3 (Fig. 3.22). The data suggests the possible involvement of 




Figure 3. 22 Interaction between MKP-2, ERK and IRF3 in vitro 
(A) HEK293T cells were transfected with HA-IRF3 with or without Flag-tagged MKP-2. 
Interaction between IRF3, ERK and MKP-2 was examined by immunoprecipitation (IP) western 
blot analysis. (B) HEK293T cells were transfected with Flag-MKP-2 with or without HA-IRF3. 
Interaction between MKP-2, ERK and IRF3 was examined by immunoprecipitation (IP) Western 
blot analysis. The data shown are a representative of 3 independent experiments with similar 
results. 
 
3.5.2 ERK inhibition decreased the expression of type-I IFNs, IL-6 and TNF-α 
It has been reported that ERK signaling is integrated to IRF3 activation and 
type-I IFNs induction in primary mouse embryo fibroblasts after myxoma virus 
infection (Wang, Ma et al. 2004). We observed that deficiency of MKP-2 
enhanced ERK and IRF3 activation in macrophages and over-expression of MKP-
2 inhibited IKKε induced IRF3 and ERK activation. Therefore, it is possible that 
MKP-2-ERK signaling is integrated to IRF3 activation and type-I IFNs induction 
in macrophages upon influenza infection. To test this, we inhibited ERK 
activation by treating the mouse macrophages cell line RAW264.7 with ERK 
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inhibitor PD98059 to examine the expression of type I Ifns and inflammatory 
cytokines in response to PR8 infection. As can be seen in Fig. 3.23, ERK was 
activated upon PR8 infection and PD98059 efficiently inhibited the ERK 
activation upon PR8 infection. Moreover, PD98059 treatment markedly reduced 
the type-I Ifns, Il-6 and Tnf-α expression in RAW264.7 after influenza virus 
infection (Fig. 3.23B). 
These data provided evidence that ERK positively regulates type-I Ifns 
expression in macrophages upon influenza virus infection. 
 
 
Figure 3. 23 ERK inhibition decreased type-I Ifns, Il-6 and Tnf-α expression in macrophage 
upon influenza virus infection 
The RAW264.7 cells were pretreated with ERK inhibitor PD98059 (100 μM) or vehicle control 
DMSO for 1 h before infected with influenza virus. (A) ERK activation and (B) genes exopression 
of type-I Ifns, Il-6 and Tnf-α were examined by qRT-PCR 6 h after infection. The data shown are a 
representative of 3 independent experiments with similar results. Data are presented as mean + 
SEM. *p<0.05, **p<0.01. 
 
3.5.3 ERK inhibition decreased type-I IFNs, IL-6 and TNF-α expression and 
production in primary MKP-2 KO cells 
Next, we examined type-I IFNs production in MKP-2 KO and WT BMDMs 
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or BMDCs post PR8 infection upon ERK inhibition. Cells were pretreated with 
ERK inhibitor PD98059 or DMSO for 1 h before infection. As shown in Fig 
3.24A, MKP-2 KO BMDMs secreted significantly higher amount of IFN-α and 
IFN-β than WT cells. ERK inhibition significantly attenuated production of type-I 
IFNs in both WT and KO cells upon infection. Importantly, MKP-2 KO BMDMs 
produced comparable level of IFN-β and TNF- as WT BMDMs, and the 
differences on the expression of IFN- and IL-6 between WT and KO cells were 
minimized by the treatment of ERK inhibition (Fig. 3.24).  
Taken together, these data suggest that MKP-2 regulates IRF3-type-I IFNs 
most likely through ERK pathway in response to influenza virus infection.  
 
 
Figure 3. 24 ERK inhibition decreased type-I IFNs, IL-6 and TNF-α production in MKP-2 
KO cells after influenza infection 
(A) WT and MKP-2 KO BMDMs were pretreated with ERK inhibitor PD98059 (100 μM) or 
DMSO for 1 h before infected with PR8 (MOI: 1) for another 24 h. Type-I IFNs production was 
examined by ELISA. (B) WT and MKP-2 KO BMDCs were pretreated with ERK inhibitor 
PD98059 (100 μM) or DMSO for 1 h before infected with PR8 (MOI: 1) for another 24 h. Type-I 
IFNs, IL-6 and TNF-α production was examined by ELISA. The data shown are a representative 





        In this study, we found that MKP-2 KO mice were resistant to influenza 
virus infection compared with WT mice, which was demonstrated by reduced 
viral loads and decreased body weight loss in the KO mice compared with WT 
mice upon PR8 infection (Fig. 3.1-3.2). We further observed increased type-I 
IFNs production and expression in the lungs from MKP-2 KO mice on day 2 and 
day 3 upon PR8 infection (Fig. 3.4-3.5), which could explain the resistant 
phenotype of MKP-2 KO mice upon influenza virus infection.  
To uncover the regulatory mechanism of type-I Ifns expression by MKP-2, 
we first compared cellular infiltration in the WT and MKP-2 KO lungs upon 
infection and observed comparable innate immune cells infiltration between WT 
and MKP-2 KO mice (Fig. 3.7-3.8), which suggest that the increase of type-I Ifns 
expression in MKP-2 KO mice P.I. is not due to increased innate immune cells 
infiltration. Increased type-I Ifns expression was further observed in MKP-2 KO 
BMDMs and BMDCs upon influenza virus infection (Fig. 3.10-3.11), which 
indicates that MKP-2 negatively regulates type-I Ifns expression in innate 
immune cells.  
        To address the mechanism by which MKP-2 regulates type-I Ifns expression 
in innate immunity, we generated BMDMs and BMDCs for experiments and 
observed that MKP-2 KO BMDMs have enhanced phospshorylation and nuclear 
translocation of IRF3 (Fig. 3.12-3.13), the master regulator of type I Ifns (Hiscott 
2007), upon influenza virus infection. The elevated IRF3 activity was further 
confirmed by increased expression of various Isgs, which are regulated by IRF3 
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(Fig. 3.14). Additionally, increased type-I Ifns expression and IRF3 activation 
were also observed in MKP-2 KO BMDMs in response to the activation of TLR3 
and RIG-I (Fig. 3.17 and 3.19). We further demonstrated that MKP-2 inhibited 
IFN-β promoter activity in response to overexpression of various components of 
IRF3 pathway including MAVS and TBK1 as well as IKKε-induced IRF3 
phosphorylation (Fig. 3.20-3.21). These data demonstrated that MKP-2 negatively 
regulates IRF3- type-I IFNs axis in response to influenza virus infection. 
Interestingly, increased ERK activation in MKP-2 KO cells was observed in 
response to PR8 infection and RIG-I stimulation (Fig. 3.15 and Fig. 3.19). 
Furthermore, we observed that MKP-2 interacts with both ERK and IRF3 (Fig. 
3.22), suggesting the possibility that MKP-2 regulates type-I IFNs expression 
through ERK-IRF3 axis upon influenza virus infection. We then utilized ERK 
inhibition approach to examine the link between MKP-2/ERK and IRF3-type-I 
IFNs in macrophages. We observed reduced influenza virus –induced type-I Ifns 
expression upon ERK inhibition (Fig. 3.23). More importantly, ERK inhibition 
minimized the differences on type-I Ifns expression between WT and MKP-2 KO 
macrophages (Fig. 3.24), further strengthening the link between MKP-2-ERK and 
IRF3-type-I IFNs. Therefore, MKP-2 negatively regulates IRF3-type-I Ifns 
expression in response to influenza virus infection, likely through its regulation on 
ERK. Through this novel mechanism, MKP-2 plays an important role in innate 
immune response against influenza virus infection.   
In the following sections, I will further discuss about the regulation of IRF3-
type-I IFNs pathway by MKP-2. The limitations of this study and possible future 
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work will also be discussed. 
3.6.1 MKP-2 KO mice are resistant to influenza infection 
Influenza infection mouse model has been widely used in studying the 
regulation of anti-viral immune response by a specific gene. Upon infection, 
influenza virus induces a massive infiltration of innate immune cells and secretion 
of important soluble factors including type-I IFNs, pro-inflammatory cytokines 
and chemokines (Perrone, Plowden et al. 2008). In this study, we employed gene 
KO mouse model to study the role of MKP-2 in innate immune response to 
influenza virus infection. We found significantly decreased viral loads in the lungs 
of MKP-2 KO mice compared with WT mice upon influenza virus infection (Fig. 
3.1). Interestingly, type-I IFNs production was significantly increased in MKP-2 
KO mice on day 2 and day 3 P.I (Fig. 3.4A and Fig. 3.5A). Furthermore, the body 
weight loss of MKP-2 KO mice was observed to be significantly lower starting 
from day 7 days P.I. until day 11 on which the mice were sacrificed (Fig. 3.2). In 
line with the decreased disease severity, the viral genes Ha and Na expression was 
observed to be significantly decreased in MKP-2 KO mice on day 11 P.I. 
compared with WT mice (Fig. 3.3).  
Type-I IFNs are known to be the major anti-viral cytokines, critically 
inhibiting virus replication through several mechanisms as discussed in the 
introduction section. Therefore, the increased type-I IFNs production in the lungs 
of MKP-2 KO mice post influenza virus infection could explain the decreased 
viral loads observed in MKP-2 KO mice. The reduced viral loads associated with 
increased type-I IFNs production in the early stages of influenza virus infection 
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further lead to the reduced disease severity in MKP-2 KO mice. Overall, these 
data consistently demonstrated a resistant phenotype of MKP-2 KO mice in 
response to influenza virus infection. 
 With the use of gene KO mouse model, MKP-1 KO mice have been 
reported to exhibit increased weight loss compared with WT mice upon influenza 
virus infection due to defective T cell activation and proliferation (Zhang, 
Reynolds et al. 2009). However, the role of MKPs in innate ani-viral response is 
rarely studied, thus our study is a pioneer to demonstrate that MKP-2 in innate 
response to virus infection. On the other hand, Al-Mutairi, Cadalbert et al. have 
demonstrated that MKP-2 KO mice were susceptible to intracellular parasite 
Leishimania Mexicana infection by regulating the expression of iNos and 
arginase-1 expression (Al-Mutairi, Cadalbert et al. 2010). The different roles 
played by MKP-2 in response to parasites and influenza virus infection could be 
explained by the different defense mechanism involved during parasite and virus 
infection. Innate anti-viral activity of the body is mainly dependent on type-I IFNs 
production whereas endogenous type-I IFNs signaling has been shown to be 
detrimental in host defence against parasite Leishimania Mexicana infection (Xin, 
Vargas-Inchaustegui et al. 2010). It will be helpful if type-I IFNs in response L. 
Mexicana that was not reported by Al-Mutairi et al. is determined. Type-I IFNs 
have also been shown to enhance susceptibility to intracellular bacteria Listeria 
monocytogenes infection (O'Connell, Saha et al. 2004, Rayamajhi, Humann et al. 
2010). Therefore, it will be interesting to find out the potential role of MKP-2 in 
immune response to L. monocytogenes infection.  
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In addition to type-I IFNs, it is important to note that pro-inflammatory 
cytokines, including IL-6 and TNF-α, were also observed to be slightly elevated 
in the lungs from MKP-2 KO mice post PR8 infection (Fig. 3.4A and Fig. 3.5A). 
IL-6 and TNF-α have been reported to play very important roles in protection 
against influenza infection in the mice (Perrone, Szretter et al. 2010, Dienz, Rud 
et al. 2012). The increased cytokines production may also contribute to local and 
systemic inflammation and virus clearance to some extent by restricting virus 
activity in epithelial cells. In consistent with the ELISA data, mRNA expression 
of type-I Ifns, Il-6 and Tnf-α was also slightly increased in the lungs of MKP-2 
KO mice compared with WT mice but not significantly. The possible explanation 
for this difference could be the different kinetics between genes expression and 
cytokines secretion in the lungs upon infection. 
3.6.2 MKP-2 negatively regulates type-I Ifns, Il-6 and Tnf-α expression in cellular 
level 
        Upon infection, influenza virus recruits massive amounts of neutrophils, 
monocytes, macrophages and DCs into the lungs, which will produce type-I IFNs, 
pro-inflammatory cytokines as well as chemokines to help the body to clear the 
viruses. In this study, we observed comparable numbers of neutrophils, 
macrophages and DCs infiltration between WT and MKP-2 KO mice (Fig. 3.7 
and 3.8) which demonstrated that increased type-I IFNs production in MKP-2 KO 
mice was not due to increase number of innate immune cells infiltration. An 
alternative explanation to this would be that deficiency of MKP-2 resulted in 
increased expression of type-I IFNs by cells such as macrophages and DCs. To 
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test this, we performed studies on BMDMs and BMDCs from WT and MKP-2 
KO mice after influenza virus infection.  
Upon PRRs stimulation, several MKPs including MKP5 and MKP1 were 
reported to negatively regulate pro-inflammatory cytokines expression by 
targeting JNK and p38 in macrophages (Zhang, Blattman et al. 2004, Zhao, Wang 
et al. 2006). PAC-1/DUSP2, on the other hand, was shown to positively regulate 
inflammatory response to PRRs stimulation through the crosstalk between JNK 
and ERK. Regarding MKP-2, Cornell et al. demonstrated that deficiency of MKP-
2 in BMDMs results in decreased pro-inflammatory cytokine productions upon 
LPS stimulation with elevated ERK activation and reduced JNK and p38 
activation (Cornell, Rodenhouse et al. 2010). In contrast, Mashael S. Al-Mutairi et 
al. reported that MKP-2 KO BMDMs exhibited increased pro-infalammatory 
cytokine production with elevated JNK and p38 activation but not ERK activation 
(Al-Mutairi, Cadalbert et al. 2010). With these controversial data reported, the 
role of MKP-2 in regulation of pro-inflammatory immune response, particularly 
to influenza virus infection, need to be further examined. Here, we observed 
MKP-2 KO BMDMs and BMDCs produce significantly higher amounts of type-I 
IFNs, IL-6 and TNF-α than WT cells upon influenza virus infection (Fig. 3.10A 
and Fig. 3.11A). In line with the increased cytokine secretion by MKP-2 KO 
cells, mRNA expression of these factors was also found to be significantly 
elevated in MKP-2 KO cells (Fig. 3.10B and Fig. 3.11B). These results 
demonstrated the negative regulation of inflammatory cytokine expression in 
macrophages and DCs and confirmed the findings on negative regulation of pro-
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inflammatory cytokines including IL-6 and TNF-α expression by MKP-2 in 
response to LPS in BMDMs reported (Al-Mutairi, Cadalbert et al. 2010). It has 
been shown that, when overexpressed, MKP-2 negatively regulates IFN-β 
promoter activity in response to LPS and poly (I:C) stimulation (McCoy, 
Carpenter et al. 2008). Our study clearly demonstrated the negative regulation of 
type I Ifns by MKP-2 in vivo and ex vivo, advanced our understanding on the role 
MKPs in innate immune response to virus infection. 
During influenza virus infection, influenza specific PAMPs possibly activate 
RIG-I and TLR3 to trigger the activation of IRF3 pathway to mediate type-I Ifns 
expression. We observed increased IRF3 phosphorylation in MKP-2 KO BMDMs 
compared with that in WT cells upon virus infection (Fig. 3.12). In line with 
increased IRF3 phosphorylation, nuclear translocation of IRF3 from cytoplasma 
was significantly increased in MKP-2 KO BMDMs post influenza infection (Fig. 
3.13). Increased IRF3 activation in MKP-2 KO cells was further supported by the 
increased expression of ISGs including Rantes, and Isg15 compared with WT 
cells upon influenza virus infection (Fig. 3.14). Isgs have been reported to target 
almost every step of influenza virus replication in the host cells to dampen the 
virus replication (Schoggins and Rice 2011).Thus, the enhanced Isgs 
expression in MKP-2 KO cells upon infection most likely contributed to the 
reduced viral loads and disease severity in the KO mice upon influenza virus 
infection. All together, the data proves that MKP-2 negatively regulates IRF3 
activation in innate immune cells upon virus infection. The results appear to 
concur with a recent study demonstrating that MKPs could render IRF3 
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hypophosphorylation through TLRs signaling by enhancing the formation of a 
MKPs-IRF3-TBK1 ternary complex (Negishi, Matsuki et al. 2013). Another study 
postulated a new mechanism of IRF3 negative regulation by a phosphatase known 
as PP2A showing that this protein terminates IRF3 mediated anti-viral responses 
by directly dephosphorylating IRF3 (Long, Deng et al. 2014). Our results, 
together with these previous findings, provide evidence that phosphatases are 
important negative regulators of IRF3-type-I IFNs, having critical roles in 
immune response to viral infection. 
        MAPKs play critical roles in regulating the expression of various pro-
inflammatory cytokines in response to microbial infections, including influenza 
virus infection. The MKP protein family critically controls the magnitude and 
duration of MAPK activation. Therefore, the activation of MAPKs was studied by 
western blot to investigate the substrates of MKP-2 in macrophages response to 
influenza virus infection. We found that upon influenza virus infection, p38 and 
ERK activation was increased but not JNK (Fig. 3.15). Surprisingly, ERK 
activation in MKP-2 KO BMDMs was higher as compared with WT cells 
whereas p38 activation was comparable (Fig. 3.15). This differs with previous 
studies, which showed that MKP-2 targets JNK and p38 in BMDMs in response 
to LPS stimulation (Al-Mutairi, Cadalbert et al. 2010). Interestingly, the same 
group subsequently reported MKP-2 to target ERK in mouse embryonic fibroblast 
(MEF) in response to PDGF stimulation (Al-Mutairi, Cadalbert et al. 2010, 
Lawan, Al-Harthi et al. 2011). A possible explanation is that MKP family 
members can target different substrates, which is dependent on the type of tissues 
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and cells, the subcellular compartments they are localized and the stimuli that 
activate MAPKs and MKPs. 
        It is worth to note that the production of IL-6 and TNF-α was upregulated in 
MKP-2 BMDMs upon virus infection associated with increased ERK activation. 
JNK and p38 are the MAPKs commonly considered to be in charge of IL-6 and 
TNF-α expression and production. However, a recent study demonstrated that in 
swine macrophages, the production of pro-inflammatory cytokines including IL-6, 
IL-8 and TNF-α was significantly induced in an ERK-dependent manner (Gao, 
Sun et al. 2012). Therefore, ERK activation is important for pro-inflammatory 
cytokines expression in macrophages in response to influenza virus infection.  
In summary, our data demonstrated that MKP-2 negatively regulates ERK 
activation to inhibit IRF3-type-I Ifns and pro-inflammatory cytokine expression 
including the expression of Il-6 and Tnf-α in innate immunity in response to 
influenza infection.  
3.6.3 MKP-2 negatively regulates type-I Ifns, Il-6 and Tnf-α expression response 
to PRRs activation 
Influenza virus infection is detected by at least three distinct classes of PRRs 
including TLRs (TLR3/TLR7/TLR8), RIG-I and NLRP3 (Pang and Iwasaki 
2012). The PAMPs generated in influenza virus-infected cells activate TLR3 and 
RIG-I that is expressed in macrophages and trigger downstream type-I IFNs 
immune responses. Upon TLR3 and RIG-I activation by respective ligands, there 
was a significant elevation of type-I Ifns and Il-6 expression in MKP-2 KO 
BMDMs (Fig. 3.17). Consistent with the results from cells infected with influenza 
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viruses, p-IRF3 and p-ERK levels were higher in MKP-2 KO BMDMs as 
compared with WT BMDMs after 5’-ppp dsRNA stimulation, whereas the 
activation and expression of other kinases were comparable between WT and 
MKP-2 KO BMDMs (Fig. 3.19). These data show MKP-2 is a negative regulator 
of type-I Ifns and pro-inflammatory cytokines expression in response to TLR3 
and RIG-I activation in macrophages. 
ssRNAs generated by influenza virus in the endosomes trigger downstream 
type-I IFNs anti-viral response by activating TLR7 which is predominantly 
expressed in DCs but not in macrophages. Therefore, BMDCs were stimulated 
with TLR7 ligand R848 to study the role of MKP-2 in TLR7 signaling. Upon 
R848 stimulation, a significant increase in expression and secretion of IFN-β, but 
not IL-6 and TNF-α, in BMDCs was observed (Fig. 3.18). However, IFN-α 
secretion was not detected upon R848 stimulation. Since TLR7 activation mainly 
triggers IRF7 signaling instead of IRF3, the regulation of type-I IFNs and pro-
inflammatory cytokines upon TLR7 activation by MKP-2 need to be further 
studied.  
Taken together, these data suggest that MKP-2 acts as a negative regulator of 
type-I IFNs in response to PRRs related to RNA viruses such as influenza viruses 
in innate immune cells. 
3.6.4 MKP-2 regulates upstream kinase-mediated IRF3 activation 
        Proteins such as MAVS and TBK1 participate in virus-triggered IRF3 
activation and IFN-β induction in response to virus infection. To further 
characterize the mechanism by which MKP-2 negatively regulates IRF3 
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activation, we examined the regulation of MKP2 on MAVS- or TBK1-induced 
IFN-β promotor activity using gene overexpression approach and found the MKP-
2 inhibited MAVS- or TBK1-induced IFN-β promotor activity (Fig. 3.20). 
Additionally, over-expression of MKP-2 greatly reduced IKKε induced IRF3 
phosphorylation in HEK293T cells (Fig. 3.21). Immunoprecipitation assay 
confirmed the interaction between MKP-2 and IRF3, which support the 
speculation that MKP-2 targets IRF3 to regulate IRF3 activation. Surprisingly, 
endogenous ERK was found to interact with both MKP-2 and IRF3. As a member 
of the MKP protein group, MKP-2 has been shown to interact with endogenous 
ERK (Nomura, Shiiba et al. 2012). The interaction between IRF3 and ERK could 
be direct or mediated by MKP-2, which we will be investigated in the future. 
Nevertheless, these findings implied the existence of an MKP-2-ERK-IRF3 axis 
that regulates type-I IFNs expression in response to influenza virus infection. 
3.6.5 Inhibition of ERK decreased type-I IFNs expression and IRF3 activation 
    ERK inhibition in epithelial cells was previously reported to inhibit IRF3 
mediated type-I Ifns expression in response to myxoma virus infection (Wang, Ma 
et al. 2004). To confirm the regulation of type-I Ifns expression by ERK in 
immune cells in response to influenza virus infection, we performed ERK 
inhibition experiments in macrophages and found that ERK inhibition 
significantly inhibited type-I Ifns, Il-6 and Tnf-α expression in response to 
influenza infection (Fig. 3.23). More importantly, ERK inhibition not only 
significantly reduced type-I IFNs production in both WT and MKP-2 KO 
BMDMs and BMDCs, but also minimized the difference on type I Ifns expression 
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between WT and KO cells (Fig. 3.24). These provide evidence that MKP-2 
regulates type-I Ifns expression in macrophages through ERK pathway in 
macrophages in response to influenza infection. However, it is still possible that 
MKP-2 directly dephosphorylate IRF3, as inhibition of ERK did not lead to equal 
expression of type-I Ifns in WT and KO cells. 
In conclusion, we found that MKP-2 plays an important role in innate 
immune response against influenza virus infection possibly through regulation of 
ERK-IRF3-type-I IFNs signaling, which advanced our understanding of the 
MKPs in innate immune responses. As shown in Fig. 3.25, upon infection, 
influenza virus induces ERK activation as well as TBK1 and IKKε mediated IRF3 
phophorylation. During the infection, MKP-2 negatively regulates ERK 
phosphorylation, which positively regulates IRF3 activation. Therefore, upon 
influenza infection, MKP-2 negatively regulates IRF3 mediated type-Ifns 
expression, which is pivotal in the control of influenza virus replication possibly 




Figure 3. 25 MKP-2-ERK-IRF3 axis regulates type-I Ifns expression upon influenza virus 
infection 
Upon infection, influenza viruses induce ERK and IRF3 activation through RIG-I and TLR3 
activtion. MKP-2 negatively regulates ERK activation, which postively regulates IRF3 mediated 
type-I Ifns expression. 
 
3.7 Limitations 
3.7.1 Animal models used in this study 
The use of in vivo animal models in this study allows for the investigation of 
the complex host/pathogen infection and host immune system, which are not 
replicable by in vitro models. Furthermore, it has been reported that MKPs can be 
cell type specific and yield different results between in vivo and in vitro models 
(Zhang and Dong 2007). Therefore, the use of in vivo model in this study 
provided a more accurate model for the study of MKP-2 in response to influenza 
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virus infection. Nevertheless, there are various issues regarding the use of animal 
model, as it is not possible to replicate the entire process of pathogenesis in 
humans. For example, mice do not exhibit fever upon infection and they lack the 
ability to transmit influenza virus. As such, the use of this mouse model can only 
be limited to the study of certain aspects of the pathogenesis and immune 
response upon influenza infection. However, it may be advantageous that there is 
a lack of viral transmission in mouse as it allows individual infected mice to be 
independent subjects receiving equal viral dosage even when housed in the same 
cage. Besides, TLR8 is non-functional in mice due to the lack of five amino acid 
(Kugelberg 2014) which makes the study not exactly applicable to humans.  
3.7.2 Influenza virus induce a weak type-I IFNs response 
NS1 is well known as virulent factor of the influenza virus. It has been shown 
that NS1 inhibits type-I Ifns expression in animal models, cell lines and primary 
cells (Garcia-Sastre 2001). The inhibition of type-I Ifns expression is due to the 
formation of NS1-RIG-I complex, which blocks the recognition of 5’-ppp dsRNA 
by RIG-I. As such, the activation of signaling pathways including MAPKs and 
IRF3 was weak as compared with other viral mimics stimulation including poly 
(I:C) and 5’-ppp dsRNA. Therefore, other virus types such as Sendai Virus (SD) 
and Vesicular Stomatitis Virus (VSV), which were also frequently used to study 
host immune response to virus infection, could be considered to study the anti-
viral response model. 
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3.7.3 Lack of MKP-2 function in lung epithelial cells 
In innate immune responses, lung bronchial epithelial cells (BECs) provide 
the first line of defense against respiratory viral infection and the effectiveness of 
this response is critically dependent on the type I IFNs (Hsu, Parsons et al. 2012). 
Since airway epithelial cells are the primary targets for influenza virus infection 
and replication (Kesic, Simmons et al. 2011), it will be good to analyze the role of 
MKP-2 in the lung epithelial cells in type-I IFNs production and controlling the 
virus replication. However, we tried to isolate the lungs to enrich the epithelial 
cells using the EasySep™ Mouse Epithelial Cell Enrichment Kit from Stem cells 
technologies. The yield of epithelial cells obtained was very low. Since 
macrophages and DCs also produce a large amount of type-IFNs in response to 
influenza infection, we studied the regulation of type-I Ifns expression by MKP-2 
in BMDMs and BMDCs. However, alveolar macrophages have been shown to not 
support productive replication of seasonal influenza viruses (Yu, Chan et al. 
2011). Therefore, our in vitro study only demonstrated the role of MKP-2 in the 
regulation of type-I Ifns expression. To illustrate the control of influenza virus 
replication in vitro, the lung epithelial cell lines may need to be used to further 
study the role of MKP-2 in controlling virus replication. 
3.7.4 Lack of MKP-2 and IRF3 double KO mouse model 
    Apart from IRF3, IRF-7 is another master regulator of type-I IFNs expression. 
Upon TLR7 activation, IRF-7 is activated and translocated into the nucleus to 
bind ISREs, resulting in the transcription of type-I Ifns, Isgs and pro-
inflammatory cytokines (Tripathi, White et al. 2013). Therefore, IRF-7 activation 
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also plays an important role in the regulation of type-I IFNs. However, the IRF-7 
activation mainly occurs in DCs upon TLR7 activation whereas in BMDMs, the 
activation is hardly detectable. Therefore, our results obtained from MKP-2 KO 
BMDMs suggest that MKP-2 regulates type-I Ifns expression through IRF3 
activation in BMDMs. However, to further confirm that MKP-2 targets IRF3 to 
regulate the anti-viral response in vivo, the MKP-2 and IRF3 double KO mice 
could be used to examine the phenotype of viral resistance to influenza infection. 
3.8 Future works 
3.8.1 In vitro p-ERK kinase assay to examine if p-ERK can directly phosphorylate 
IRF3 in vitro 
IRF3 is found in an inactive cytoplasmic form, which upon serine/threonine 
phosphorylation forms a complex with CREBBP (Au, Moore et al. 1995). This 
complex translocates to the nucleus and activates the transcription of type-I Ifns, 
as well as other Isgs (Yoneyama, Suhara et al. 1998). Our results indicate the ERK 
pathway is involved in IRF3 activation in response to influenza infection. ERKs 
are known to directly phosphorylate many transcription factors including Ets-1, c-
Jun and c-Myc (Chang, Steelman et al. 2003). Therefore, it would be interesting if 
we can further confirm that p-ERK can directly phosphorylate IRF3 and mediate 
IRF3 nuclear translocation. As such, pERK and IRF3 will be enriched and 
purified by protein A/G beads and incubated in the kinase buffer to carry out an in 
vitro kinase assay. After incubation, the samples will be preceded to examine 
IRF3 phosphorylation by western blot. 
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3.8.2 Investigate the role of MKP-2 in regulation of immune response against 
other RNA viruses 
In this study, we only performed the experiments all by a single influenza 
virus strain PR8. We found that MKP-2 negatively regulates the type-I Ifns 
expression in response to PR8 infection. Due to the inhibitory mechanism of type-
I Ifns expression by NS1 present in WT influenza virus, the type-I IFNs responses 
are not robust. To further comfirm that MKP-2 negatively regulates anti-viral 
response to other kinds of virus infection, Sendai virus and VSV will be used in 
both in vivo and in vitro analysis. 
3.8.3 Examine if deficiency of MKP-2 can protect mice from influenza lethal 
infection 
In this study, we showed that MKP-2 KO mice are resistant to influenza 
infection by reducing the viral loads in the lungs and decreased weight loss as 
compared with WT mice. Another aspect of the phenotype would be survival 
curve of the mice after lethal dosage of influenza virus infection. As such, we are 
going to further study a lethal dosage infection model to confirm the increased 
protective response to influenza infection in MKP-2 KO mice.  
3.8.4 Examine the adaptive immune response to influenza infection 
    Type-I IFNs have a key role in the clonal expansion, memory formation and 
priming of adaptive T cells including both CD4+ and CD8+ T cells responses in 
the initial phase of antigen recognition (Kolumam, Thomas et al. 2005, Huber and 
Farrar 2011). Since adaptive CD4+ and CD8+ T cells and humoral specific 
antibody secretion are critical in the final clearance of influenza virus. Therefore, 
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we will analyze the adaptive virus specific T cells responses and humoral virus 
specific antibody responses upon influenza virus infection in MKP-2 KO mice. 
3.8.5 Examine the pathology of lungs after influenza infection  
        Apart from the protective role of pro-inflammatory cytokines produced by 
the infiltrated immune cells, excessive cells infiltration and production of pro-
inflammatory cytokines could be detrimental to the host, which will cause lung 
inflammation and injury. Therefore, histology analysis of the lung tissues in both 
WT and MKP-2 KO mice after infection will give a better understanding of the 
















Chapter 4 MAP Kinase Phosphatase 2 regulates macrophage-
adipocyte interaction and inflammation in response to FFA 
4.1 Nutrition conditions modulate the expression of Mkp-2 in adipose tissue 
Adipose tissue dysfunction is a primary defect in obesity and obesity-
associated metabolic disorders such as type 2 diabetes (Bluher 2009). To examine 
the possible role of MKP-2 in the function of adipose tissue in obesity, C57BL/6J 
mice were fed with a high fat diet (HFD) for 8 weeks. The relative mRNA 
expression of Mkp-2 in WAT was quantified.  
We found significantly reduced Mkp-2 expression in WAT from HFD-fed 
mice than that from mice fed with normal chow (NC) (Fig. 4.1). We further found 
that the expression of MKP-2 in the stromal vascular cells (SVCs) from WAT was 
significantly higher than that in total WAT (Fig. 4.1). These results suggested a 
possible role of MKP-2 in WAT and infiltrated cells in the regulation of obesity 
development.  
 
Figure 4. 1 Mkp-2 expression in adipose tissue 
C57BL/6J mice were fed with a HFD for 8 weeks. (A) The expression of Mkp-2 in WAT was 
examined. (B) The Mkp-2 expression in the SVF was examined by qRT-PCR compared with total 
WAT. The data shown are a representative of 3 independent experiments with similar results. Data 
are presented as mean + SEM. *p<0.05. 
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4.2 Expression of Mkp-2 in macrophages increased in response to FFA 
stimulation 
In obesity, increased release of FFAs result in the activation of inflammatory 
signaling pathways, recruitment of macrophages, and the production of 
inflammatory mediators, which contribute to the development of metabolic 
disorders such as insulin resistance (Boden 2008). ATMs are the major source of 
inflammatory cytokines in adipose tissue (Olefsky and Glass 2010). To 
understand the regulation of inflammatory cytokine expression by MKP-2 in 
obesity, we assessed the expression of Mkp-2 in macrophages in response to 
palmitate, one of the most abundant saturated FFAs in plasma (Weigert, Brodbeck 
et al. 2004). Murine macrophage cells, RAW264.7, were stimulated with 
palmitate for various periods of time and the expression of MKP-2 was 
determined by qRT-PCR and western blot analysis.  
As shown in Fig. 4.2A, Mkp-2 mRNA expression was significantly increased 
at 3 and 6 h after FFA stimulation when compared with cells without stimulation. 
In line with the increased mRNA expression of Mkp-2, we detected increased 
MKP-2 protein expression in RAW264.7 cells at 9 and 12 h post palmitate 
stimulation (Fig. 4.2B). Therefore, FFAs increases Mkp-2 expression in 
macrophages, suggesting the regulatory function of MKP-2 in FFA-induced 




Figure 4. 2  Mkp-2 expression in RAW264.7 in response to palmitate stimulation 
RAW264.7, were stimulated with 50 μM palmitate for various periods of time and the expression 
of Mkp-2 was determined by qRT-PCR (A) and western blot (B). The data shown are a 
representative of 3 independent experiments with similar results. Data are presented as mean + 
SEM. *p<0.05, **p<0.01, ***p<0.001. 
 
4.3 MKP-2 inhibits TNF-α production and JNK activation in macrophages 
upon palmitate stimulation 
To further understand the role of MKP-2 in FFAs-mediated inflammatory 
cytokine expression in macrophages, we transfected the promoter of AP1, the 
major target of MAP kinase pathways (Wagner and Nebreda 2009), with mouse 
MKP-2 full length cDNA construct or vector control in RAW264.7 cell. Dual 
luciferase assay was performed to assess AP-1 promoter activity in response to 
FFAs stimulation. We observed that upon palmitate stimulation, AP-1 promoter 
activity increased and overexpression of MKP-2 in RAW264.7 cells significantly 




Figure 4. 3 Regulation of AP-1 promotor activity in RAW264.7 response to palmitate 
stimulation by MKP-2 
RAW264.7 cells were transfected with the promoter of AP1 with mouse MKP-2 full-length cDNA 
construct or vector control in RAW264.7 cell. Dual luciferase assay was performed to assess AP-1 
promoter activity in response to 50 μM FFA stimulation. The data shown are a representative of 3 
independent experiments with similar results. Data are presented as mean + SEM. *p<0.05, 
***p<0.001. 
 
        To elucidate the regulatory role of MKP-2 in inflammatory cytokine 
expression in response to FFAs, we generated RAW264.7 cells stably expressing 
mouse MKP-2. qRT-PCR and western blot analysis were used to confirm the 
overexpression of Mkp-2 in the stable cell line. The results demonstrated that both 
mRNA and protein expression of MKP-2 in RAW264.7 cells stably expressing 
MKP-2 were significantly increased compared with cells transfected with vector 




Figure 4. 4 Mkp-2 expression in MKP-2 stably transfected RAW264.7 cells 
Overexpression of Mkp-2 in MKP-2 stably transfected RAW264.7 cells were confirmed by qRT-
PCR and western blot. Data are presented as mean + SEM. **p<0.01. 
 
Adipose tissue derived TNF-α, mainly from ATMs, is a MAP kinase target 
gene and has been shown to be a major player in obesity-induced insulin 
resistance and type 2 diabetes (Hotamisligil, Shargill et al. 1993, Steinberg, 
Michell et al. 2006, Ouchi, Parker et al. 2011). To examine the role of MKP-2 in 
the regulation of TNF-α expression in macrophages in response to FFAs, we 
stimulated MKP-2 overexpressing cells and control cells with different dosages of 
palmitate. Consistent with previous studies, palmitate induced TNF-α secretion in 
a dose-dependent manner in RAW264.7 cells (Shi, Kokoeva et al. 2006) (Fig. 
4.5). Overexpression of MKP-2 greatly inhibited TNF-α production in response to 




Figure 4. 5 MKP-2 inhibits TNF-α production response to FFA stimulation in RAW264.7 
RAW264.7 cells that were stably expressing MKP-2 and pcDNA vector were stimulated with 
different concentrations of palmitate overnight. The supernatants were collected to examine the 
TNF-α production by ELISA. The data shown are a representative of 3 independent experiments 
with similar results. Data are presented as mean + SEM. *p<0.05, **p<0.01. 
 
It has been shown previously that MKP-2 is a negative regulator of p38 and 
JNK in BMDMs in response to LPS stimulation (Al-Mutairi, Cadalbert et al.). To 
further study the mechanism of MKP-2 in regulating TNF-α expression in 
macrophages in response to FFAs, MKP-2 overexpressing macrophages and 
control cells were stimulated with palmitate to examine MAP kinase activation. 
We found that JNK activation was increased at 3 and 6 h upon FFA stimulation 
(Fig. 4.6). Interestingly, overexpression of MKP-2 in macrophages significantly 
decreased the activation of JNK in response to palmitate (Fig. 8.6) whereas p38 
activity could not be detected under the same condition.  
Taken together, the results indicated that in response to FFAs, MKP-2 




Figure 4. 6 Regulation of JNK activation by MKP-2 in RAW264.7 response to FFAs 
stimulation 
(A) MKP-2 stably transfected RAW264.7 cells and vector transfected cells were stimulated with 
FFAs for indicated time points and the JNK activation were measured by western blot. The data 
shown are a representative of 3 independent experiments with similar results. (B) Densitometry 
analysis of immunoblots showing mean + SEM from 3 independent experiments normalized to 
total JNK. *p<0.05. 
 
4.4 Overexpression of MKP-2 in macrophages suppresses inflammatory 
cytokines production during macrophage-adipocyte interaction 
Previous reports demonstrated that there is a paracrine loop between 
adipocytes and macrophages, which aggravates inflammatory changes (Suganami, 
Nishida et al. 2005). Therefore, we employed an in vitro adipocyte-macrophage 
co-culture system to further study the regulation of MKP-2 on inflammation 
during adipocyte-macrophage interaction.  MKP-2 overexpressing macrophages 
were seeded directly onto the differentiated 3T3-L1 adipocytes and cultured for 
24h with or without palmitate. Interestingly, the expression of inflammatory 
cytokines IL-6, TNF- and chemokine MCP-1 was significantly increased in the 
co-culture system of macrophages and adipocytes even without palmitate 
stimulation (Fig. 4.7). FFAs stimulation significantly increased the expression of 
IL-6 and TNF-, but not MCP-1. Importantly, overexpression of MKP-2 in 
macrophages significantly suppressed the production of inflammatory mediators 
including IL-6, TNF-α and MCP-1 with or without palmitate stimulation (Fig. 
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4.7). These results demonstrated that MKP-2 is a negative regulator of 
inflammation during adipocyte-macrophage interaction. 
 
 
Figure 4. 7 Overexpression of MKP-2 in macrophages suppresses inflammatory cytokines 
production during adipocyte-macrophage interaction 
105 RAW264.7 cells and differentiated 3T3-L1 cells were cultured alone or together and 
stimulated with or without 750 μM palmitate overnight. IL-6, TNF-α and MCP-1 production in the 
supernatants were determined by ELISA. The data shown are a representative of 3 independent 
experiments with similar results. Data are presented as mean + SEM. *p<0.05, **p<0.01. 
 
4.5 Overexpression of MKP-2 in macrophages inhibits macrophage M1 
activation 
Obesity is accompanied by macrophage infiltrating into adipose tissue and 
transition of ATM polarization from M2 to M1 activation status (Lumeng, Bodzin 
et al. 2007).  M1 or classically activated macrophages accumulated in adipose 
tissue can produce various inflammatory mediators such as IL-6 and TNF- to 
promote the development of insulin resistance (Krausgruber, Blazek et al. , Xu, 
Dembski et al. 2003). M2 or alternatively activated macrophages, on the other 
hand, are necessary to maintain glucose homeostasis (Zaslona, Wilhelm et al.). To 
examine the function of MKP-2 in the regulation of macrophages activation 
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status, control and MKP-2 overexpressing macrophages were stimulated with M1 
stimulators LPS (100 ng/mL) and IFN-γ (20 ng/mL). We observed that in 
response to M1 activation, MKP-2 overexpressing macrophages produced 
significantly reduced amount of IL-6 and TNF-α compared with control cells 
(Fig. 4.8). The expression of Il12p40, one of the M1 markers, was also 
significantly decreased in MKP-2 overexpressing cells (Fig. 4.8). The data 
indicate that overexpression of MKP-2 inhibits macrophage M1 activation.  
 
 
Figure 4. 8 Overexpression of MKP-2 inhibits macrophage M1 activation 
Vector and MKP-2 stably transfected RAW264.7 were stimulated with 20 ng/mL IFN-γ + 100 
ng/mL LPS for 12 h. (A) The M1 markers including IL-6, TNF-α production were examined in the 
supernatants after stimulation. (B) M1 marker Il-12p40 was examined by qRT-PCR. The data 
shown are a representative of 3 independent experiments with similar results. Data are presented 
as mean + SEM. *p<0.05, **p<0.01. 
 
To examine the target of MKP-2 in response to M1 activation, the activation 
of ERK, JNK and p38 was determined by western blot analysis. We found that the 
activation of all the three groups of MAP kinases was induced at 30 min and 
weaned off 3 h after M1 stimulation in macrophages (Fig. 4.9). Overexpression of 
MKP-2 significantly inhibited the activation of JNK and p38, but not ERK, in 
response to M1 stimulation (Fig. 4.9). Together, the results indicated that MKP-2 




Figure 4. 9 Overexpression of MKP-2 inhibits p38 and JNK activation in response to M1 
activation 
(A) Vector and MKP-2 stably transfected RAW264.7 were stimulated with 20 ng/mL IFN-γ + 100 
ng/mL LPS for the indicated time points. MAPKs activation was examined in the whole cell 
lysates after stimulation by western blot. The data shown are a representative of 3 independent 
experiments with similar results. (B) Densitometry analysis of immunoblots showing mean + 
SEM from 3 independent experiments normalized to total ERK, JNK and p38. *p<0.05, **p<0.01, 
***p<0.001. 
 
4.6 Overexpression of MKP-2 in macrophages enhances macrophage M2 
activation 
The results from above experiments prompted us to examine if MKP-2 is 
required for macrophages M2 activation. To address this, we stimulated MKP-2 
overexpressing cells and control cells with IL-4 to induce M2 activation. The gene 
expression of M2 markers including Arg1, Chi3l3, Mgl1 and IL-10 were 
significantly increased in MKP-2 overexpressing cells upon IL-4 stimulation 
compared with control cells (Fig. 4.10A). Furthermore, we also found that 
overexpression of MKP-2 increased the expression of M2 markers in response to 
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IL-13 which is also known to induce M2 activation in macrophages (Fig. 4.10B). 
In summary, MKP-2 modulates macrophage phenotypic switch by inhibiting M1 
activation and promoting M2 activation. The finding implies a possible role of 
MKP-2 in systemic insulin resistance by regulating phenotypic switch of ATMs 
during the development of insulin resistance. 
 
 
Figure 4. 10  Overexpression of MKP-2 in macrophages enhances macrophage M2 activation 
Vector and MKP-2 stably transfected RAW264.7 were stimulated with 20 ng/mL IL-4 or IL-13 for 
12 h. M2 markers including Arg1, Chi3l3, Mgl1 and Il-10 expression were examined by qRT-
PCR. The data shown are a representative of 3 independent experiments with similar results. Data 
are presented as mean + SEM. *p<0.05, **p<0.01, ***p<0.001. 
 
4.7 JNK and p38 inhibition in macrophages inhibits macrophage M1 
activation 
To further confirm the involvement of JNK and p38 in macrophage M1 
activation, we performed JNK and p38 inhibition experiments in macrophages in 
response to M1 activation. The RAW264.7 cells were pretreated with 20 μM of 
JNK inhibitor SP100625 or 20 μM of p38 inhibitor SB23580 respectively for 1h 
before activation by M1 activators. The inhibition of JNK or p38 activation was 
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confirmed by probing for p-JNK and p-ATF2, which is p38 specific downstream 
target, as shown in Fig. 4.11A. After M1 activation, the production of IL-6 and 
TNF-α in the supernatants collected was measured by ELISA. It was observed 
that JNK inhibition significantly inhibits IL-6 and TNF-α production upon M1 
activation in macrophages whereas only IL-6 production but not TNF-α was 
observed to be significantly reduced by p38 inhibition (Fig. 4.11B). These data 
indicate that JNK and p38 are involved in the M1 activation of macrophages. 




Figure 4. 11  JNK and p38 inhibition inhibit M1 activation in macrophages 
RAW264.7 cells were pretreated with 20 μM JNK inhibitor SP100625 or p38 inhibitor SB23580 
for 1 h before treated with M1 activators. (A) JNK activation and ATF2 activation were examined 
by western blot respectively to confirm the inhibition of JNK and p38. (B) IL-6 and TNF-α 
production in the supernatants were examined by ELISA. The data shown are a representative of 3 
independent experiments with similar results. Data are presented as mean + SEM. *p<0.05, 
**p<0.01, ***p<0.001. 
 
In summary, in response to FFAs stimulation, MKP-2 negatively regulates 
TNF-α production. Meanwhile in response to M1 activation, MKP-2 negatively 
 114 
regulates both IL-6 and TNF-α. On the other hand, MKP-2 positively regulates 
macrophage M2 activation. The data suggest that MKP-2 modulates macrophage 
phenotypic switch by inhibiting M1 activation and promoting M2 activation. The 
finding implies a possible role of MKP-2 in systemic insulin resistance by 
regulating adipose tissue inflammation status.  
4.8 Discussion 
Obesity is associated with chronic inflammation in adipose tissue (Wellen 
and Hotamisligil 2003). MAP Kinase pathways are essential regulators of 
inflammation. As major negative regulators of MAPKs, the role of MKPs in 
immune responses has been under extensive investigation recently. However, the 
functions of MKPs in chronic inflammation in adipose tissue have not been fully 
investigated. In this study we aimed to elucidate the role of MKP-2 in regulating 
the inflammation status during adipocyte-macrophage interaction. The significant 
finding of this study was that MKP-2 was demonstrated for the first time to have a 
negative regulatory role in inflammatory response during adipocyte-macrophage 
interaction, which implies a possible role of MKP-2 in the initiation of adipose 
tissue insulin resistance. 
In the following sections, I will further discuss about the regulation of 
inflammation status during adipocyte-macrophage interaction by MKP-2. The 
limitations of this study and possible future work will also be discussed. 
4.8.1 Mkp-2 expression in adipose tissue 
In this project, we firstly observed that Mkp-2 expression decreased in 
adipose tissue upon HFD feeding (Fig. 4.1) which suggest a potential role of 
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MKP-2 in the regulation of adipose tissue function. Furthermore, we observed 
increased Mkp-2 expression in SVFs isolated from normal chow mice compared 
with total WAT (Fig. 4.1). The SVFs consist of preadipocytes, fibroblasts, 
vascular endothelial cells and immune cells (Uysal, Tobita et al. 2012). This 
implies that Mkp-2 expression in SVFs may play a major role in the function of 
adipose tissue. ATMs in SVFs play a key role in causing inflammation and 
linking obesity to insulin resistance (Sell, Habich et al. 2012). Hence, we further 
stimulated murine macrophage cell line RAW264.7 with FFAs and observed an 
increased Mkp-2 expression after stimulation (Fig. 4.2), which indicates that 
MKP-2 is possibly involved in the process of FFAs induced adipose tissue 
inflammation and insulin resistance.  
4.8.2 MKP-2 negatively regulates TNF-α production in response to FFA 
stimulation 
FFAs have been shown promote inflammation, which in turn contributes to 
the development of insulin resistance (Shi, Kokoeva et al. 2006). As TNF-α is 
known to be the major inflammatory mediator, which induces insulin resistance in 
adipose tissues (Hotamisligil 1999), we first investigated the role of MKP-2 in the 
regulation of TNF-α production in response to FFAs. A significant reduction of 
TNF-α production was observed in MKP-2 overexpressing RAW264.7 upon 
stimulation (Fig. 4.5). Additionally JNK activation was induced by FFA 
stimulation and found to be greatly impaired in MKP-2 overexpressing cells (Fig. 
4.6). Activation of JNK and p38 is well known to regulate the production of 
various inflammatory cytokines including TNF-α, IL-1 and IL-6. Our results 
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indicated that overexpression of MKP-2 in RAW264.7 inhibited pro-inflammatory 
cytokine TNF-α production upon FFA stimulation by inactivating JNK activity. 
This is in agreement with previous observations that MKP-2 negatively regulates 
pro-inflammatory cytokine production in response to LPS stimulation. However, 
here we found that p38 activation is not induced by FFAs, which indicate that 
upon FFA stimulation, MKP-2 specifically targets JNK to regulate inflammatory 
cytokine production. Our results validate previous studies, which showed that 
FFAs activate ATMs via TLR4 and JNK-dependent pathways (Nguyen, 
Favelyukis et al. 2007).  
 
4.8.3 Overexpression of MKP-2 inhibits inflammation during adipocyte-
macrophage interaction 
Recently, it was proposed that there is a paracrine loop involving adipocyte-
derived FFAs and macrophage-derived TNF-α, which could lead to a vicious 
cycle that aggravates inflammatory changes in obese adipose tissue (Suganami, 
Nishida et al. 2005). Similarly, our results showed a significant increase of pro-
inflammatory cytokine production including IL-6, TNF-α and MCP-1 during 
adipocyte-macrophage contact interaction (Fig. 4.7). Interestingly, overexpression 
of MKP-2 in macrophages significantly decreased the overall pro-inflammatory 
cytokines production in the co-culture system (Fig. 4.7). Hence, it provides 
evidence that by negatively regulating inflammatory cytokine expression in 
macrophages, MKP-2 inhibits the inflammation during adipocyte-macrophage 
interaction, supporting that macrophages infiltrating into adipose tissue in obesity 
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is the major source of inflammatory cytokines. Interestingly, macrophage 
interaction with adipocytes without FFA stimulation triggers inflammatory 
cytokine expression (Fig. 4.7). A possible explanation of the observations would 
be that basal levels of FFAs released from adipocytes induce less TNF-α 
production in macrophages, which in turn induce increased lipolysis in adipocytes 
to release FFAs (Souza, Palmer et al. 2003). Another possibility is that the 
interaction between macrophages and adipocytes through unidentified molecules 
triggers the activation of inflammatory pathways such as JNK pathway to induce 
inflammatory cytokine expression. Of note, adipocytes are also able to produce 
pro-inflammatory cytokines induced by FFAs (Jiao, Ma et al. 2011). The 
mechanism underlying the activation of inflammatory cytokine expression with 
exogenous FFA needs to be further investigated. Nevertheless, our study 
demonstrated an important role of MKP-2 in inhibition of inflammation during 
macrophage-adipocyte interaction. 
4.8.4 MKP-2 modulated macrophage M1 and M2 activation 
During HFD-induced insulin resistance development, ATMs undergo a 
phenotypic switch from anti-inflammatory M2 to pro-inflammatory M1, during 
which the macrophages lose their protective capacity to maintain insulin 
sensitivity (Lumeng, Bodzin et al. 2007). Here, we observed that overexpression 
of MKP-2 inhibits macrophages M1 activation while promotes macrophage M2 
activation. During M1 activation, MKP-2 specifically inhibits p38 and JNK 
activation which have been shown to regulate pro-inflammatory cytokines 
production through transcription factor AP-1 (Fig. 4.9) (Pulverer, Kyriakis et al. 
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1991). This is in agreement with previous observations in MKP-2 KO BMDMs in 
response to LPS stimulation (Al-Mutairi, Cadalbert et al.). Furthermore, JNK and 
p38 inhibition decreased IL-6 and TNF-α production in response to macrophage 
M1 activation, which confirmed that JNK and p38 promote macrophage M1 
activation (Fig. 4.11).  
Interestingly, upon M2 activation, MKP-2 overexpressing RAW264.7 
express higher amounts of M2 macrophages markers (Fig. 4.10). Unlike M1 
activation, JNK and p38 activation were not detectable after M2 stimulation. In 
M2 culture condition, IL-4 or IL-13 triggers downstream pathways including 
STAT6 signaling to regulate the expression of M2 markers including Chi3l3 and 
Arginase-1 (Villanueva and Tontonoz 2010). Therefore, apart from MAPKs, 
MKP-2 might target other proteins to regulate the expression of these genes 
during M2 macrophage activation. In fact, there are evidences suggesting STAT 
proteins as substrates of MKPs (Najarro, Traktman et al. 2001, Sekine, Tsuji et al. 
2006). The regulatory mechanism M2 activation in macrophages by MKP-2 
remains to be deciphered. 
MKPs including MKP-2 have been well studied in regulating inflammatory 
cytokine expression in response to microbial infection. However the regulation of 
adipose tissue inflammation by MKPs is not well understood. Our work for the 
first time demonstrates that MKP-2 expression in macrophages is important for 
macrophage phenotypic switching from M1 to M2, thereby inhibiting 
inflammation during adipocyte-macrophage interaction. Therefore, this study 
implies that MKP-2 has a potential role in the regulation of inflammation in 
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4.9.1 In vitro co-culture system 
However, the limitation of the study is that adipose tissue is a very 
complicated tissue, which consists of various cell types including immune cells, 
epithelial cells and preadipocytes that make it difficult to mimic in vitro. Co-
culture of two cell types: adipocytes and macrophages, although they are the two 
major cell types involved in the development of insulin resistance, is not ideal for 
study the development of inflammation and insulin resistance in obesity. The 
modulation of macrophage phenotypic switch by other populations of immune 
cells such as T cells and eosinophils in adipose tissue cannot be addressed in this 
in vitro co-culture system. Therefore, an in vivo model would be a better choice to 
further understand the function of MKP-2 in adipose tissue. 
4.9.2 Is the function of MKP-2 restricted to hematopoietic cells in altering 
inflammation status during adipocyte-macrophage interaction? 
  Our data suggested that overexpression of MKP-2 in macrophages inhibits 
inflammation during adipocyte-macrophage interaction. However, it should be 
noted that adipocytes are also able to secrete pro-inflammatory mediators 
including IL-6, TNF-α and MCP-1 (Fain, Madan et al. 2004). Therefore, it is 
important to examine the regulation of MKP-2 on inflammation in both 
adipocytes and macrophages. To address this, intracellular immunostaining 
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should be used to further study the origins of these cytokines during adipocyte-
macrophage interaction. Primary cells including adipocytes and macrophages 
from MKP-2 KO mice could be isolated to analyze inflammatory response to FFA 
stimulation. Additionally, global MKP-2 KO, macrophage- and adipocyte-specific 
MKP-2 conditional KO mice will be useful for elucidating the function of MKP-2 
in these two cellular compartments in obesity induced inflammation and insulin 
resistance.  
        To further understand if MKP-2 expression in macrophages could improve 
insulin sensitivity, the activation of insulin-mediated signaling pathways will be 
examined. To confirm the in vitro data, in vivo MKP-2 KO mice model will be 
used to study the role of MKP-2 in adipose tissue inflammation and insulin 
resistance. Furthermore, conditional macrophage specific MKP-2 KO mice will 
be used to study the development of age- and diet-induced adipose tissue 











Chapter 5 Conlusions and final discussion 
5.1 Main findings of influenza infection project 
In this project, we demonstrated that MKP-2 KO mice exhibit a phenotype 
of decreased viral loads and body weight loss upon influenza virus infection. This 
corresponds to the increased type-I IFNs production, which contributes to the 
clearance of influenza virus.  
Furthermore, we demonstrated that MKP-2 KO BMDMs and BMDCs 
secreted significantly higher amount of type-I IFNs as well as pro-inflammatory 
cytokines upon influenza virus infection. The activation of IRF3 was observed to 
be enhanced in MKP-2 KO BMDMs upon influenza virus infection compared 
with WT BMDMs. Over-expression of MKP-2 inhibits MAVS, TBK1 induced 
IFN-β promoter activity and IKKε mediated IRF3 phosphorylation. These data 
consistently suggest MKP-2 as a negative regulator of type-I IFNs expression.  
ERK has been further found to interact with both MKP-2 and IRF3 in vitro. 
Inhibition of ERK inhibits type-I IFNs and pro-inflammatory cytokines 
expression in both WT and MKP-2 KO BMDMs upon influenza virus infection to 
a comparable level, which suggests a possible novel mechanism in the regulation 
of IRF3 activation through an MKP-2-ERK-IRF3 axis. A recent study 
demonstrated that activated ERK could directly phosphorylate IRF3 in vitro 
(Moore and Petro 2013). However, if this is functional during influenza infection 
still need to be studied. 
To summarise, deficiency of MKP-2 has a protective role in anti-viral 
responses to influenza virus infection. Therefore, MKP-2 could potentially serve 
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as a drug target to aid in the alleviation of health care burden imposed by 
influenza epidemics. 
5.1 Main findings of macrophage-adipocyte co-culture project 
        Additionally, we also employed an in vitro co-culture system to study the 
role of MKP-2 in regulating the inflammation status during macrophage-
adipocyte interaction. Our results demonstrated that overexpression of MKP-2 
inhibited TNF-α expression in response to FFAs in macrophages. Overexpression 
of MKP-2 inhibited macrophage M1 activation and promoted macrophage M2 
activation. Importantly, overexpression of MKP-2 in macrophages suppressed 
inflammation during adipocyte-macrophage interaction. Our data suggested a 
potential inhibitory role of MKP-2 in adipose tissue inflammation, which plays a 
causative role in the development of obesity-induced insulin resistance. Future 
studies will be focused on the elucidating the function of MKP-2 in regulating 
macrophage M1/M2 activation and chronic inflammation in obesity in vivo, 
which could be beneficial for the development of novel therapeutic intervention 
by targeting MKP-2 and MKP-2 regulated signaling. 
5.1 Final discussion 
        In this project, we demonstrated that MKP-2 regulates type-I Ifns expression 
in response to influenza infection and M1/M2 macrophage activation through 
differential regulation of MAP Kinases. In response to influenza infection, we 
found that MKP-2 targets ERK in BMDMs, whereas in macrophage cell line 
RAW264.7, MKP-2 targets JNK and p38. As a member of MKPs family, MKP-2 
belongs to subgroup 1 (Caunt and Keyse 2013). Therefore, it has similar 
preference to target all the three MAPKs including ERK, JNK and p38 in vitro. 
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For instance, MKP-2 has been reported to target ERK in MEFs after PDGF 
stimulation (Al-Mutairi, Cadalbert et al. 2010, Lawan, Al-Harthi et al. 2011). 
Meanwhile, another study showed that MKP-2 targets JNK and p38 in BMDMs 
after LPS stimulation (Al-Mutairi, Cadalbert et al. 2010). The differential 
regulation of MAP Kinases by MKPs could be possibly explained that MKP 
family members can target different substrates depending on the type of tissues 
and cells, the subcellular compartments they are localized and the stimuli that 
activate MAPKs and MKPs.  
        In this study, upon influenza infection, JNK activation was not detected and 
p38 activation was not very strong. Therefore, it is possible that upon influenza 
infection, ERK activation was dominant over JNK and p38; as a result, excessive 
MKP-2 binds to ERK to dephosphorylate ERK instead of JNK and p38. However, 
upon M1 activation, all the three MAPKs were all strongly activated. In 
macrophages, MKP-2 was possible prone to bind to JNK and p38 over ERK. The 
competition mechanism results in the differential targets of MAPKs in 
macrophages response to influenza infection and M1 activation. Besides, JNK has 
also been reported to have negative crosstalk with ERK in inflammatory cell 
signaling and effector functions (Jeffrey, Brummer et al. 2006). Therefore, 
decreased JNK activation in MKP-2 overexpressing RAW264.7 leads to increased 
ERK activation to a similar level with pcDNA3.1 transfected RAW264.7 after M1 
activation. However, the differential regulation of MAPKs activation by MKP-2 
and crosstalks among MAPKs need to be further studied. 
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